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ACE – Angiotensin converting enzyme 
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BMI – Body mass index 
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CAD – Coronary artery disease  
CHDH – Choline dehydrogenase  
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CRP – C-reactive protein 
CVD – Cardiovascular disease 
DMG – Dimethylglycine  
DDH – Dimethylglycine dehydrogenase 
GAM – Generalized additive model 
GFR – Glomerular filtration rate 
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HDL-C – High density lipoprotein cholesterol 
ICC – Intraclass correlation coefficient 
IDI – Integrated discrimination index 
HR – Hazard ratio 
LDL-C – Low density lipoprotein cholesterol 
LME – Linear mixed effects model  
LVEF – Left ventricular ejection fraction 
MMA – Methylmalonic acid 
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MS – Methionine synthase 
NAFLD – Non-alcoholic fatty liver disease 
NRI – Net reclassification improvement 
NORVIT – Norwegian Vitamin Trial 
PCI – Percutaneous coronary intervention 
PPAR – Peroxisome proliferator-activated receptor 
ROC-AUC – Receiver operating characteristics-area under the curve  
RCT – Randomized controlled trial 
SAH – S-adenosylhomocysteine 
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STROBE-ME – STrengthening the Reporting of OBservational studies in 
Epidemiology-Molecular Epidemiology 
tHcy – Total homocysteine 
TMAO – Trimethylamine N-oxide 
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UAP – Unstable angina pectoris 
VLDL – Very low density lipoprotein 
WECAC – Western Norway Coronary Angiography Cohort 
WENBIT – Western Norway B vitamin Intervention Trial 
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SCIENTIFIC ENVIRONMENT 
The current thesis is based upon studies of two Norwegian cohorts, made up of 
patients with suspected and/or verified coronary heart disease (CHD); The Western 
Norway Coronary Angiography Cohort (WECAC) and the Norwegian B-vitamin 
Intervention Trial (NORVIT). Although the NORVIT was a multicentre national 
intervention study, the scientific environment of the current thesis has mainly been 
localized to the University of Bergen, with Professor Ottar Kjell Nygård as main 
supervisor and Professor Per Magne Ueland and PhD Eva Ringdal Pedersen as co-
supervisors. However, the work has been a joint collaboration with other local and 
national research environments, including the Western Norway Cardiovascular 
Registry (WENOCARD), the Cardiovascular Disease in Norway (CVDNOR) project, 
the KG Jebsen Center for Diabetes Research, and Bevital AS, as well as scientific co-
workers at the Department of Heart Disease, Haukeland University Hospital and 
Stavanger University Hospital, and the Norwegian University of Science and 
Technology. 
Funding of the current project has mainly been provided by the University of 
Bergen in terms of a four-year full-time PhD scholarship, but also by the Western 
Norway Regional Health Authority and the Foundation to Promote Research into 
Functional Vitamin B12 Deficiency. 
6 
ACKNOWLEDGEMENTS 
I first met Dr Ottar Nygård in 2000, when working as an assistant in the Department of 
Heart Disease at Haukeland University Hospital. Little did I know of his many projects 
at that time, but soon I found myself in front of a computer plotting WENBIT patient 
data into the CORDOBA database. At first this meant little more to me than some 
extra and much appreciated money, but I soon gained more interest into the field of 
cardiology and continued to work on the database also after graduating in 2003. Upon 
returning to Bergen in 2006 I felt that everyday clinical practice left little room for 
academic work. However, my recent hospital internship had ignited an interest in 
academia, and despite much reluctance from my side, the then appointed professor 
Nygård convinced me into starting the current research project in 2009, thereby 
introducing me to scientific work. For that I am extremely grateful. Ottar, your 
philosophy of supervision is based upon the necessity for your students to work 
independently, and without you having the need for a detailed control of every aspect 
of their work. This economic exertion of leadership reflects trust in your employees, 
and for me this has been essential for being able to carry out the work upon which this 
thesis rests. Your open-mindedness and truly academic approach, the way you 
promote your students, and how you unselfishly share your vast knowledge as well as 
extremely hard earned data is nothing but inspirational. 
I am also most grateful to my co-supervisors professor Per Magne Ueland and 
PhD Eva Ringdal Pedersen for their time and effort spent in both critically reviewing 
my manuscripts and sharing their expertise within the fields of biochemistry, 
epidemiology and science in general. To be given the chance to work with 
international top scientists, I cannot be anything but humble. Per, I know PhD 
supervision may feel as a slow-going phlebotomy to you, but I hope I have not left you 
critically anaemic.  
Further, I thank all my co-authors for their contributions in all aspects of the 
scientific work, not least because of their hard effort with the WECAC and NORVIT 
databases, the latter being chaired by professor Kaare Harald Bønaa at the University 
of Tromsø. A special tribute goes to professor Grethe Tell at the Department of Global 
7 
Public Health and Primary Care, University of Bergen and to Tomislav Dimoski at 
The Norwegian Knowledge Centre for the Health Services, Oslo, for their efforts made 
in the CVDNOR project. I feel honoured of being allowed to use these exceptionally 
fine data in my work. Not least, I thank the study participants in the WECAC and 
NORVIT cohorts for their invaluable contribution to the current work.  
I also wish to thank the scientific environment both within our research group at 
the Department of Preventive Cardiology, Haukeland University Hospital, and our 
extended group, comprising scientists and staff at Bevital AS. Apart from your 
important scientific input, you have provided many laughs and good times, and the 
annual vitamin meetings abroad definitively have served as highlights. A special 
tribute is also paid to Britt Gjellefall, for your devoted and professional attitude 
towards work, for your great humour and for the sincere care you take of your 
colleagues. During the last four years I have also shared office with my colleagues and 
co-authors Hall, Reinhard, Kjetil and Jonas. Our microenvironment has consisted of 
not only low oxygen tension and tons of teenage humour, but also important 
discussions on politics, history, statistics, science, and not least the hits in the face that 
life provides. Thank you.    
Although my interest for cardiology was sparked on early during my student 
years, it was consolidated when carrying out my hospital internship under the guidance 
of Dr Ulf Hurtig. As a brilliant clinician and firm believer in evidence based medicine, 
you are an inspiration for carrying out both clinical and scientific work. 
Although highly inspirational and rewarding, this journey has at times also felt 
strenuous and frustrating. I simply would not have been able to make it without the 
support from my closest family; to my mother Grethe and father Jan Erik, thank you 
for your unconditional love, confidence and support that you have showed me 
throughout my life. Thanks also to my brother Kjetil, my sister-in-law Anna, to my 
uncle Svein and aunt Grethe, and to my family-in-law Karen, Terje and Espen. 
Finally, Renathe, this work is dedicated to my true life companions: you, 
Tobias, Vebjørn and Håvard. I love you. 
Gard Frodahl Tveitevåg Svingen, 




The choline oxidation pathway comprises the sequential metabolism of choline into 
betaine, dimethylglycine (DMG), and sarcosine. In addition, dietary choline and 
betaine can be turned into trimethylamine N-amino oxide (TMAO). Alterations in 
choline metabolism may relate to cardiovascular disease (CVD) and type 2 diabetes 
(T2D). Several investigations have focused on systemic concentrations of choline and 
betaine; however large-scale prospective data are scarce. There is therefore a need for 
more comprehensive assessments of choline metabolites in relation to incident CVD, 
T2D and mortality, in addition to investigating any potential benefit in risk prediction 
from such biomarkers.  
AIM 
We carried out observational cohort studies of the prospective relationships between 
plasma DMG and incident acute myocardial infarction (AMI) and mortality, as well as 
the association between systemic and urinary choline metabolites with the risk of 
incident T2D. The biomarkers’ impact on model discrimination and reclassification of 
patients at risk was also assessed, as were their test-retest reliabilities and temporal 
trends according to B-vitamin treatment. 
MATERIALS AND METHODS 
Analyses on the association between plasma DMG and incident AMI, as well as the 
relationships between choline metabolites and incident T2D were performed among 
patients evaluated for suspected stable angina pectoris (SAP). The risk assessment 
between plasma DMG and mortality included SAP patients and patients with AMI 
from an independent cohort. Clinical endpoint data were obtained from regional and 
national health registries. Endpoint analyses on incident AMI and mortality were 
carried out by Cox regression, whereas analyses on incident T2D were performed by 
logistic regression. Model discrimination and reclassification were explored by 
calculating the C-statistics, the integrated discrimination index (IDI), and the 
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continuous net reclassification improvement (NRI>0), respectively. Mixed linear 
modelling was used for assessing temporal trends in metabolite concentrations. 
RESULTS 
Higher plasma DMG was associated with several traditional risk factors for coronary 
heart disease (CHD). After about four and a half years of follow-up, plasma DMG 
showed linear relationships with incident AMI among 4154 patients with suspected 
SAP (age, gender and fasting adjusted hazard ratio (HR) for the fourth vs. first quartile 
(95% confidence intervals (CI)) 1.95 (1.42-2.68); P<0.001). The relationship between 
plasma DMG and incident AMI was particularly strong among non-smokers and 
patients with lower serum apoB and triglyceride levels (P for interaction≤0.03).  
Among essentially the same patients, as well as among 3733 patients with AMI 
who were followed for 7 years, higher plasma DMG was also associated with 
increased risk of all-cause mortality (age and gender adjusted HRs (95% CIs) for the 
fourth vs. the first quartile 1.72 (1.21–2.46) and 1.76 (1.42–2.18) among SAP and 
AMI patients, respectively) and CVD mortality (HRs (95% CIs) 1.94 (1.21–3.11) and 
1.97 (1.50–2.59) among SAP and AMI patients, respectively). The associations were 
only slightly attenuated when adjusting for established CHD risk factors, to which 
adding plasma DMG also improved risk prediction for both AMI and all-cause 
mortality. Moreover, plasma DMG showed good to excellent within-person 
reproducibility throughout repeated measurements among patients not receiving 
supplementation with folic acid + vitamin B12. 
In general, higher plasma choline and lower plasma betaine and serum sarcosine 
levels were associated with an adverse risk profile of T2D. In urine, most choline 
metabolites were positively related to an adverse diabetes risk profile. After an average 
follow-up of 7.5 years, 233 (6.4%) out of 3621 non-diabetic patients were registered 
with new-onset T2D. Incident T2D was strongly inversely associated with plasma 
betaine and positively related to urine betaine, DMG and sarcosine (age, gender and 
fasting adjusted odds ratios (95% CIs) per 1 SD increment 0.72 (0.62-0.83), 1.25 
(1.09-1.43), 1.22 (1.06-1.40), and 1.30 (1.13-1.49), respectively). We did not find any 
relationship between choline or TMAO and incident T2D. The estimates were not 
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materially altered when adjusting for a range of traditional T2D risk factors and 
potential confounders, and were similar in sensitivity analyses. Among the choline 
metabolites associated with new-onset T2D in univariate analyses, plasma betaine and 
urine sarcosine were most strongly related to incident T2D, and both indices also 
enhanced risk prediction when added to the multivariate model.  
After 1 year, as compared to placebo treatment, supplementation with folic acid 
+ vitamin B12 lowered plasma DMG and sarcosine, but increased plasma betaine and 
choline. No alterations in plasma TMAO were observed. In urine, we observed similar 
responses to supplementation as to those seen in blood. 
CONCLUSION AND IMPLICATIONS 
Among patients with suspected or verified SAP, high plasma DMG was related to 
increased risk of AMI, as well as all-cause and CVD mortality, the latter endoints 
being validated among patients with AMI. Moreover, plasma DMG improved risk 
prediction of both AMI and mortality.  
Lower plasma betaine and higher urine betaine, DMG and sarcosine 
concentrations were related to incident T2D. Plasma betaine and urine sarcosine also 
improved reclassification of patients at risk. Plasma DMG and betaine, as well as urine 
sarcosine showed good to excellent within-subject reproducibility among patients not 
supplemented with folic acid + vitamin B12, justifying one-time assessment of 
biomarker status.  
Our observational findings suggest novel pathophysiological pathways involved 
in conditions heavily impacting the global burden of disease, warranting more research 
into the field of one-carbon and choline metabolism in relation to life-style related 
diseases. 
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1 INTRODUCTION 
1.1 CARDIOVASCULAR DISEASE  
1.1.1  DEFINITION, EPIDEMIOLOGY AND IMPLICATIONS 
Cardiovascular disease (CVD) comprises all diseases of the circulatory system (i.e. 
heart and blood vessels). CVD related mortality has dropped in several countries, 
including Norway (Figure 1), during the last decades,1 and this decline has largely 
been attributed to the identification and improvement of CVD risk factors.2 Yet, CVD 
is still the number one cause of mortality globally, accounting for about one third of all 
deaths,1 and ischemic heart disease (IHD) is considered the main cause of years lost 
due to illness and death.3 In Europe, about 4 out of every 10 deaths before the age of 
75 years are due to CVD.4 Accordingly, in 2012, 13 010 and 4 852 deaths out of 
totally 41 913 deaths in Norway were attributed to CVD (International Classification 
of Diseases (ICD) 10 codes I00-I99) and IHD (ICD 10 codes  I20-25), respectively, 
emphasizing CVD as the number one cause of death nationwide.5  
Figure 1. Death from cardiovascular disease (blue line) and ischemic heart disease (red line) as 
percentages of death from all causes in Norway, during the period 1969-2012. 
Data obtained from Statistics Norway.5 
Most incident CVD events do not immediately cause death; hence CVD has a 











among individuals in Norway has only recently emerged via the Norwegian 
Cardiovascular Disease Registry (NCDR),6 contrasting other Scandinavian countries 
which have had similar national registries for many years.7, 8 On the other hand, The 
Western Norway Cardiovascular Registry (WENOCARD; 
http://cvdnor.b.uib.no/wenocard) has served as a precursor of the NCDR, by recording 
regional data on CVD hospitalizations in Western Norway public hospitals from 1972 
and throughout 2006.9 Likewise, the Cardiovascular Disease in Norway (CVDNOR; 
https://cvdnor.b.uib.no/) project collected data on prevalent and incident CVD, as well 
as diabetes mellitus, from 42 Norwegian public hospitals in the period 1994-2009. 
According to the NCDR, approximately 330 000 patients received at least one 
CVD diagnosis at Norwegian public hospitals in 2013, and almost 60% had incident 
disease.6 About 15 000 cases of AMI (ICD-10 I210-I229) were registered and over 
23 000 admissions to public hospitals and out-patient clinics were classified as due to 
angina pectoris (ICD-10 I200-I209). These data correspond to previous reports from 
regional Norwegian surveys, indicating that the prevalence of non-fatal CVD was 
approximately 9% among subjects older than 40 years, and mostly related to IHD.10  
Apart from individual human repercussions, CVD also has a major impact on 
societal health expenditures and lost productivity. According to a recent report from 
the European Heart Network and the European Society of Cardiology, the annual 
overall economic cost from CVD in Europe as per 2009 was estimated to 
approximately €196 billion. Of these expenses, IHD constitutes about 1/3, with over 
60% being related to direct health care expenditures and costs related to lost 
productivity.11  
1.1.2 PATHOPHYSIOLOGY AND CLINICAL PRESENTATION OF IHD 
Most cases of IHD are caused by atherosclerosis in the coronary arteries (i.e. coronary 
artery disease (CAD)). The pathophysiological mechanisms involve deposition of 
apolipoprotein (apo) B and cholesterol containing low-density lipoproteins (LDLs) 
inside the vessel wall at one or several locations in the coronary artery tree. This is 
accompanied by low-grade cellular inflammation, smooth muscle-cell proliferation, 
and fibrosis, forming an atherosclerotic plaque. The plaque may grow both outwards 
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(positive remodeling) and into the vessel lumen (negative remodeling). An inward 
growing plaque can potentially obliterate blood flow, giving rise to clinical features of 
coronary heart disease (CHD) on physical or emotional exertion. Such lesions can be 
visualized by coronary angiography and quantitatively graded according to luminal 
obstruction. Symptoms of CHD may vary, but typically include chest pain (i.e. angina 
pectoris), and result from insufficient blood supply to the distal myocardium to 
accommodate increased need of oxygen (i.e. ischemia).12 In patients with stable angina 
pectoris (SAP) due to reversible ischemia, symptoms will typically arise on a certain 
level of physical or psychological exertion, and relieved once the precipitating factor is 
removed or when taking medications that lessen myocardial oxygen expenditure. 
However, coronary blood flow may be obliterated, either gradually by a growing 
plaque itself, or abruptly by a thrombus generated on the plaque surface (i.e. 
atherothrombosis), to such a degree that myocardial cell death occurs distal to the 
lesion. Myocardial necrosis due to ischemia is the very definition of an acute 
myocardial infarction (AMI),13 and puts the patient at risk of both immediate and long-
term complications, such as systolic heart failure and cardiac arrest. It is noteworthy, 
however, that even the presence of non-obstructing coronary atherosclerotic lesions 
carries a significant risk of atherothrombotic events.14  
The Framingham Heart Studies have established high age, male gender, 
dyslipidemia, smoking and hypertension to predict CVD events with an accuracy of 
approximately 80% among presumably CVD naïve subjects.15 Although causality 
between established risk markers and endpoints has been heavily debated, the 
hypothesis of LDL-cholesterol (LDL-C) deposition in atheromatosis has been 
strengthened by the favorable results on CVD events and mortality from LDL-C 
lowering therapy by statins.16 Statins act primarily by inhibiting the rate-limiting step 
of the endogenous cholesterol synthesis, thereby enhancing the hepatic clearance of 
circulating LDLs by increasing the amount of LDL receptors on surface of the 
hepatocytes.17 Furthermore, intravascular ultrasound studies have suggested reductions 
in focal atherosclerotic plaque volume, as well as altered plaque composition by 
intensive statin treatment,18 indicating that statin therapy might affect the 
atherosclerotic plaque more directly. This highlights that atherosclerosis is dynamic, 
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and that reverse cholesterol transport, as facilitated by high-density lipoproteins 
(HDLs), might also be influenced by statin treatment. Although some argues against 
their alleged pleiotropic effects,19 statins may have beneficial effects on CVD beyond 
those of lipid modification.20 On the other hand, statins do not eliminate 
atherosclerosis, as an incident major cardiovascular event will still occur in a 
substantial proportion of patients who receive statin therapy.16 This residual risk may 
be because of inadequate improvement of lipid status,21 but also due to the presence of 
other known21 and unknown factors influencing risk of atherothrombosis. 
Taken together, CVD in general, and CHD in particular, are major determinants 
of morbidity and death, with huge individual and socioeconomic costs. Intense focus 
on preventive measures has likely reduced the burden of disease; however, there is still 
considerable residual risk, warranting research into novel pathophysiological 
pathways. 
1.2 DIABETES MELLITUS 
1.2.1 DEFINITION, EPIDEMIOLOGY AND IMPLICATIONS  
The term diabetes mellitus comprises diseases characterized by hyperglycemia. 
Although highly simplified, diabetes can generally be divided into states of either a 
primary and absolute insulin deficiency (type 1 diabetes), or relative insulin 
insufficiency due to insulin resistance and pancreatic β-cell dysfunction (type 2 
diabetes (T2D)), as well as gestational diabetes and rarer etiologies primarily arising 
from disorders of the pancreas.22 The current thesis will mainly deal with T2D. 
Diabetes is on the rise worldwide, and the International Diabetes Federation has 
estimated the global prevalence among adults to 8.3% (382 million people) in 2013, 
with an expected rise of more than 50% in the next 25 years. Most prevalent and 
incident cases are due to T2D, and the increase will likely have a particularly strong 
impact on younger people in developing countries.23  
The Norwegian Diabetes Register estimates the prevalence of diabetes among 
adults in Norway to be approximately 4%,24 which is comparable to our neighboring 
Scandinavian countries.25, 26 Accordingly, the Norwegian Prescription Database 
reported that 170 000 Norwegian citizens used antidiabetic drugs (The Anatomical 
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Therapeutic Chemical (ATC) classification system and the Defined Daily Dose A10) 
in 2014,27 constituting about 3% of the current total Norwegian population. In 
addition, several patients with T2D do not receive pharmacological antidiabetic 
treatment, and the International Diabetes Federation states that almost half of all 
prevalent cases of T2D in the world are likely not diagnosed.23 Hence, the real 
prevalence of T2D in Norway is almost certainly much higher than officially claimed. 
According to the Global Burden of Disease project, diabetes ranks 14 in terms 
of causing disability-adjusted life years worldwide,3 and diabetes was estimated to 
account for about 11% of total global health care expenditures in 2013.23 In Norway, a 
diagnosis of diabetes was registered in 2.5% of the consultations in general practice in 
2014,28 and 2.4% of the admissions to public somatic hospitals and out-patient clinic 
visits in 2014.29 In addition, diabetes may be the underlying cause or accompanying 
condition of a range of other illnesses, and in particular CVD.23 Diabetes therefore has 
a huge impact on individuals, public health care and the society as a whole, and 
motivates research into novel pathophysiological mechanisms in order to prevent 
disease development and its complications. 
1.2.2 PATHOPHYSIOLOGY AND CLINICAL PRESENTATION OF T2D 
The pathophysiology of T2D is complex and has yet to be fully delineated; however 
the main focus has been on insulin resistance, which is defined as the need of 
supernormal insulin excretion from pancreatic β-cells to keep blood sugar levels 
within the normal range,30 and being strongly linked to increasing bodyweight and 
physical inactivity.31 However, the β-cells may eventually be unable to compensate for 
the insulin resistant state, hence hyperglycemia ensues.31 T2D pathophysiology is also 
associated with factors other than insulin resistance and β-cell failure per se, such as 
impaired pancreatic α-cell function, genetic and epigenetic regulation, factors related 
to the diet and the gastrointestinal system, lipotoxicity, and alterations in the kidneys, 
adipose tissue and the nervous system.31, 32 
The clinical presentation of diabetes varies and symptoms may have slow onset. 
Typical symptoms of hyperglycemia include polydipsia and blurred vision, whereas 
the inability to utilize glucose as an energy source may lead to fatigue and weight 
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loss;33 however, many patients with T2D have little or no symptoms, contributing to 
the delay of diagnosis.  
1.2.3 T2D AND CHD ARE STRONGLY RELATED 
The clinical implications of T2D are severe, and excessive mortality is closely related 
to CVD,34 and in particular increased risk of CHD.35 T2D and atherosclerotic CVD 
(ACVD) seem to act additively in terms of adverse prognosis, and T2D may be 
regarded as a CHD and stroke equivalent.36 Conversely, patients diagnosed with CHD 
are at higher risk of developing T2D, but it is not known whether this association is 
explained by already impaired glucose homeostasis inherent to CHD in the first 
place.37  
T2D is further linked to atherosclerosis by multiple common risk factors, which 
may be related to insulin resistance and hyperinsulinemia,31, 38 but could also involve 
other elements, such as alterations in amino acid metabolism.39, 40 In addition, several 
pharmacological treatment options for CVD (i.e. beta-blockers, thiazides, niacin and 
statins) are associated with adverse glucose control, as well as increased risk of 
incident T2D,41 and the use of several glucose lowering drugs (including 
thiazolidinediones and sulfonylureas) have been associated with higher cardiovascular 
risk.42, 43
The close associations between T2D and CVD suggest that these two non-
communicable diseases may not only share some common soil,44 but also have 
complementary relationships yet to be resolved. Furthermore, although the diabetes 
epidemic has been suggested to curtail the steadily declining CHD mortality rates 
observed during recent decades,2 there are evidence that increasing rates of obesity and 
diabetes have not proportionately impacted CVD mortality rates.45 Although this 
discrepancy may be influenced by methodological shortcomings,45 actions to identify 
specific diabetic phenotypes particularly prone to CHD seem pertinent. 
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1.3 THE CHOLINE OXIDATION PATHWAY  
1.3.1 A BRIEF OVERVIEW  
Choline is a quaternary ammonium compound which probably enters the 
mitochondrion via a specific carrier-mediated transport mechanism.46 It is metabolized 
into betaine via a two-step reaction, catalyzed by the enzymes choline dehydrogenase 
(CHDH) and betaine aldehyde dehydrogenase (BADH), respectively (Figure 2).47  
Betaine diffuses out into the cell cytosol, and is demethylated into dimethylglycine 
(DMG), as it donates one methyl group to homocysteine (Hcy), which is converted 
into methionine. This irreversible reaction is catalyzed by the enzyme betaine-
homocysteine-S-methyl transferase (BHMT).48 DMG then enters the mitochondrion 
and is demethylated into sarcosine and glycine via the enzymes dimethylglycine 
dehydrogenase (DDH) and sarcosine dehydrogenase (SDH), respectively, with 
tetrahydrofolate (THF) being the methyl group acceptor in both reactions. Whereas 
DMG can only be produced from betaine, sarcosine may also be obtained by the 
methylation of glycine in the cell cytosol, catalyzed by glycine-N-methyltransferase 
(GNMT).49 
1.3.2 CHOLINE AND BETAINE CAN BE PRODUCED ENDOGENOUSLY OR 
OBTAINED FROM THE DIET 
In the human body most choline is present as the phospholipid phosphatidylcholine 
(PC),47 which can be converted to free choline by phospholipases.50 PC production 
takes place in the liver mainly from choline via the three-step Kennedy (CDP) 
pathway, or alternatively from phosphatidylethanolamine (PE) by the enzyme 
phosphatidylethanolamine N-methyltransferase (PEMT);51 however this endogenous 
production is insufficient for biological choline demands,47 making choline an 
essential nutrient. According to the US Institute of Medicine, the average 
recommended daily choline intake is 550 mg and 425 mg/day for men and women, 
respectively,52 but the intake varies extensively, with certain populations probably 
having insufficient intakes.53 Nordic authorities have not specifically implemented 
dietary choline intake in their current nutrition guidelines.54 Among dietary factors 
explored in a Norwegian general population sample, only eggs and cholesterol intake 
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significantly predicted plasma choline, although various other food items are rich in 
choline, as well.55 
Figure 2. The coinciding choline and methionine cycle pathways.  
BADH, betaine aldehyde dehydrogenase; BHMT, betaine-homocysteine-S-methyltransferase; CHDH, 
choline dehydrogenase; DDH, dimethylglycine dehydrogenase; DMG, dimethylglycine; GNMT, glycine-
N-methyltransferase; MAT, methionine adenosyltransferase; MS, methionine synthase; MTs, various 
methyltransferases; SAH, S-adenosylhomocysteine; SAHH, S-adenosylhomocysteine hydrolase; SAM, 
S-adenosylmethionine. 
Betaine may also be obtained directly through the diet, and plasma betaine has 
shown strong positive relations with the intake of high-fiber bread,55 a common food 
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item in Nordic countries.56 However, no recommendations on betaine intake currently 
exist. Besides, no population surveys on either choline or betaine intake have hitherto 
been carried out in the Nordic countries, thus representative intake and status of 
choline and related metabolites are largely unknown for subjects immediately 
comparable to those investigated in this thesis.  
1.3.3 RAMIFICATIONS OF CHOLINE METABOLISM  
Apart from serving as the source of downstream metabolites, choline is important for 
the synthesis of neurotransmitters, and PC is crucial in the assembly of cell membranes 
and lipoproteins,47 as well as the production of bile.50 Hence, choline species are found 
in various tissues, but downstream metabolism of free choline seem most abundant in 
the liver and the kidney,47, 50, 57 which also have highest activities of both CHDH58 and 
BADH.59, 60
CHDH is located to the inner mitochondrial membrane, and in humans the 
greatest CHDH activity has actually been found in the kidney, followed by the liver.58 
Moreover, CHDH uses flavin adenine dinucleotide (FAD) as a cofactor, and the 
electron is transferred to the respiratory chain via coenzyme Q10.58  
BADH is located both in the cell cytosol and inside the mitochondrial matrix.59 
It uses NAD+ (and NADP+) as a cofactor in the irreversible oxidation of betaine 
aldehyde,61 and is inhibited by its substrate, betaine aldehyde. BADH is found in 
several different tissues47, 62, but betaine is mainly found in the liver and kidney of 
mammals.57 This probably reflects the role of betaine not only as a methyl donor, but 
also as a regulator of cell volume (i.e. as an osmolyte), which is considered of 
particular importance in the extremely hypertonic environment of the renal cortex. 47, 57  
As expected, the main tissue distributions are similar for betaine as for BHMT, 
a Zn-containing enzyme which makes up approximately 0.6-1.6% of the total hepatic 
protein content,48 the vast amount highlighting the important role for betaine in liver 
metabolism. The BHMT pathway is involved in regulating levels of methionine and 
the non-protein amino acid, homocysteine (Hcy). It therefore tightly links betaine to 
folate metabolism, since methionine also can be formed via folate- and cobalamin- 
dependent remethylation of Hcy by methionine synthase (MS). Methionine is 
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important in protein synthesis, but also for the production of the ubiquitous methyl 
donor S-adenosylmethionine (SAM). SAM is necessary for a whole range of 
transmethylation reactions, including the production of creatine, PC and polyamines, 
as well as in DNA methylation and epigenetic regulation,63 the latter referring to the 
modification of genetic expression without altering the genomic sequence per se.64 The 
demethylation of SAM yields S-adenosylhomocysteine (SAH), which can be further 
hydrolyzed into Hcy, hence completing the so-called methionine cycle. Accordingly, 
the BHMT and MS pathways are complementary to each other. Although the latter 
pathway traditionally has received the greater attention regarding Hcy remethylation, 
BHMT might be more important in regulating Hcy levels than previously 
appreciated.48,65 The significance of the BHMT pathway in terms of methylation status 
has been emphasized by in vitro and in vivo studies where impaired BHMT flux leads 
to lower hepatic SAM levels.65-67  
The relationship between the MS and the BHMT pathways is further illustrated 
by several studies suggesting that BHMT flux seems to be inversely related to folate 
status.48, 68 BHMT activity is also inhibited by DMG and SAM, and insulin, growth 
hormone, thyroxin and testosterone, as well as hypertonicity may reduce BHMT 
activity and/or transcription.48 Methionine also inhibits BHMT,69 and it follows that 
BHMT is up-regulated when dietary intake of methionine is low and intake of labile 
methyl groups is high.70, 71 However, dietary methionine excess may also up-regulate 
BHMT,72 reflecting dual roles of the BHMT pathway in terms of methionine and Hcy 
homeostasis.73 In contrast, increased intakes of choline and betaine up-regulate BHMT 
flux, as do diabetes,74, 75 as well as treatment with glucocorticoids.48  
Hcy is degraded via the vitamin B6-dependent transsulfuration pathway, which 
is initiated by the condensation of Hcy and serine, catalyzed by cystathionine-β-
synthase (CBS). The transsulfuration pathway is essential for the making of 
cystathionine and cysteine, being pivotal in the production of the intracellular 
antioxidant glutathione, as well as for taurine and protein synthesis.69 It follows that 
inborn errors of CBS lead to Hcy accumulation, and traditionally, betaine has been 
used in the treatment of such patients.76 Not only does betaine supplementation 
increase the remethylation of Hcy into methionine, but increased BHMT flux also 
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stimulates the transsulfuration pathway,77 most probably due to increased SAM levels 
which activate CBS.69  
DDH and SDH are vitamin B2-dependent enzymes78, and assumed to have tight 
connections with the mitochondrial respiratory chain, which utilizes the electrons 
provided during DMG and sarcosine catabolism.79 Methyl groups from DMG and 
sarcosine are transferred to THF, forming 5, 10-methylenetetrahydrofolate. Hence, 
folate availability may influence the metabolism of DMG and sarcosine, although 
experimental studies suggest that folate status does not determine the passage of 
electrons to the electron transfer proteins.80 Besides generating methyl groups and 
electrons, DMG has no other known direct metabolic role, although DMG 
supplementation has been associated with altered immune responses,81-83 as well as 
having potentially favorable effects on glucose and lipid homeostasis, oxidative stress, 
and lung vasculature in poultry.84 Sarcosine may be a scavenger of excess methyl 
groups via increased GNMT flux, in particular among patients with impaired SDH.85 
Further, demethylation of sarcosine via SDH yields glycine, which is involved in 
glucose metabolism, the synthesis of nucleotides, proteins and antioxidants, as well as 
in cellular signaling.86  
The concentrations of DMG and sarcosine in tissues other than the liver and the 
kidneys have been investigated only to a limited degree, as most studies have reported 
on their blood or urinary levels. DMG was found in rectal cancer cells,87 and sarcosine 
has been reported in prostate cancer cells49 and in the rat cerebral cortex.88 
Nonetheless, studies in animals and/or humans indirectly suggest the presence of 
DMG and/or sarcosine also in various other tissues, due to their contents of DDH 
and/or SDH and/or GNMT (Table 1). Since DMG can only be obtained via the BHMT 
reaction, tissues containing DDH, but not BHMT, may therefore depend upon the 
import of DMG.  
Determinants of circulating DMG and sarcosine concentrations have not been 
extensively investigated, but DMG levels increase according to higher intake of 
metabolic precursors and especially betaine,89, 90 as well as in patients with chronic 
renal disease.91 The minor A allele on the single nucleotide polymorphism (SNP) 
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BHMT 742 G>A (R239Q),92 is inversely related to plasma DMG,93 although not 
associated with plasma total Hcy (tHcy) levels.92 Polymorphisms of the sdh gene 
influence plasma DMG levels as well,94 and even genetic traits coding for impaired 
Table 1. Tissue specificity of enzymes taking part in downstream choline metabolism 
Enzyme Tissue Species 
CDH Protein  Liver and kidney58 Human 
BADH Protein Liver95  Rat 
Kidney96 Pig 
BHMT Protein Liver, kidney48 Human 
Pancreas48 Sheep 
Optical lens48 Rhesus monkey 
DDH mRNA Liver, kidney, heart, brain, lung97 Rat 
Protein Liver, kidney, lung, heart, spleen, brain97 Rat 
SDH mRNA Liver, kidney, lung, thymus, oviduct, prostate, 
seminal vesicle, heart and brain.98 
Rat 
Protein Breast cancer tissue99 Human 
Liver, pancreas and adrenal gland.98 Rat 
GNMT Protein Liver, kidney, pancreas, salivary gland, jejunum100 Various 
mammals, 
mainly rats. 
BADH, betaine aldehyde dehydrogenase; BHMT, betaine homocysteine S-methyltransferase; CHDH, 
choline dehydrogenase; DDH, dimethylglycine dehydrogeanse; GNMT, glycine N-methyltransferase; 
SDH, sarcosine dehydrogenase. 
methylenetetrahydrofolate dehydrogenase (MTHFD1) activity are associated with 
higher hepatic and plasma DMG concentrations, possibly due to a greater demand for 
one-carbon units obtained through the choline oxidation pathway.101  
1.3.4 CHOLINE AND BETAINE METABOLISM IN THE GUT 
– THE FORMATION OF TRIMETHYLAMINE-N-OXIDE
Dietary choline, and to a lesser extent betaine, may be transformed into trimethylamine 
(TMA) by bacteria in the gut, and TMA can be further oxidized into trimethylamine 
N-monoxide (TMAO) by hepatic flavine monoxidase 3 (FMO3).102 Systemic TMAO 
levels may therefore reflect choline intake, and the gut microbiome might also be 
regarded as a choline and betaine metabolizing organ.  
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1.3.5 CHOLINE AND BETAINE IN RELATION TO HEPATIC LIPID 
METABOLISM 
Both choline and betaine are involved in hepatic lipid metabolism, and especially in 
the export of lipids from the liver. Not only is free choline used in the production of 
PC, but PEMT uses three molecules of SAM in the alternative production of PC from 
PE, thus highlighting the need of adequate methylation status for this reaction to occur. 
The BHMT pathway may also be more directly related to hepatic lipid metabolism as 
suggested by specific concomitant genetic transcriptions of hepatic bhmt and apob 
mRNA.103 Accordingly, BHMT induction by betaine supplementation resulted in 
increased production and secretion of VLDL from the liver; however systemic apoB 
and triglyceride levels were not affected. 103 This was possibly due to increased hepatic 
clearance via the LDL receptor,103 suggesting an overall increased transport of apoB 
containing lipoproteins and cholesterol between the liver and extrahepatic tissues. In 
humans high-dose betaine supplementation has been associated with a relative increase 
in serum LDL-cholesterol, and supplementation with both choline and betaine 
modestly increases serum triglycerides.104 Accordingly, increased availability of 
choline and betaine has been inversely related to non-alcoholic fatty liver disease 
(NAFLD),47 which is strongly associated with T2D and considered an independent 
CVD risk factor.105  
1.3.6 HOMOCYSTEINE AS A CARDIOVASCULAR RISK FACTOR 
– A LONG STORY MADE SHORT
Since the last half of the 20th century there has been a great focus on the strong 
relationship between high levels of tHcy (the sum of all Hcy species) in blood and 
urine, and risk of occlusive CVD (Figure 3). The associations are based upon firm data 
from numerous epidemiological and experimental studies, suggesting 
hyperhomocysteinemia to be a causal risk factor for ACVD beyond those identified by 
the Framingham Heart Studies.106 Moreover, the solution to the problem seemed 
straightforward, as well as inexpensive and tolerable, because the administration of 
folic acid and/or vitamin B6 lowers circulating tHcy by increasing Hcy remethylation 
or degradation. Hence, several trials with such therapy in order to reduce CVD risk 
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were launched in the late 1990s and early 2000s; however, despite substantial tHcy 
lowering effects by the interventions, no improvement in prognosis were observed,107 
nor did later Mendelian randomization studies immediately support elevated tHcy as a 
causal risk factor for ACVD.108, 109 In fact, treatment with folic acid and vitamin B12 
in the WENBIT was associated with accelerated growth of atherosclerotic plaques.110 
Consequently, the limelight has faded on the “homocysteine theory” (Figure 3), 
indicating that increased plasma tHcy is merely an epiphenomenon of other pathways 
responsible for increased CVD risk. 
Figure 3. Yearly number of articles indexed in the Pubmed/Medline database by the 
medical subheadings “homocysteine” + “cardiovascular disease” during the last 30 years.  
Data obtained from www.pubmed.com 
1.3.7 CHOLINE METABOLISM IN RELATION TO CVD AND DIABETES 
Small population studies have related higher systemic choline levels to adverse 
cardiovascular risk, and even suggested that choline in whole blood and serum may 
yield incremental prognostic information beyond that conferred by conventional risk 
markers among patients with suspected acute coronary syndrome (ACS; i.e. either 
unstable angina pectoris or AMI).111 Accordingly, observational data from a 
Norwegian general population sample showed that high plasma choline and low 
























elevated blood pressure and serum triglycerides, and low serum high-density 
lipoprotein-cholesterol (HDL-C).112 On the other hand, a study among about 500 
patients with a recent ACS found U-shaped associations between plasma and urine 
betaine with risk of incident AMI and hospitalizations for heart failure, respectively.113 
Notably, the same study also reported as a secondary finding that increased plasma 
DMG levels were related to CVD events and mortality.113 A small study found higher 
urine DMG, but not betaine, in patients with than without premature vascular 
disease,114 and another reported the BHMT 742 G>A minor allele to be inversely 
related to the extent of angiographic CAD among elderly patients.92 In summary, these 
observations indicate that higher circulating choline and DMG levels might reflect 
adverse CVD risk, whereas the risk relationships with betaine seem a bit more 
complex. In addition, a recent series of preclinical and human studies has suggested 
plasma TMAO to play a role in ACVD, and that reducing choline intake might be a 
means of risk reduction,102, 115 despite earlier general population based studies 
reporting no associations between intakes of neither choline nor betaine and CVD 
risk.116, 117
Circulating choline levels according to diabetes status are not well established;47 
however a recent small cross-sectional study from China suggested lower serum 
choline and betaine concentrations in association with prevalent diabetes and diabetic 
complications.118 An inverse association between systemic betaine and existing T2D 
has been supported by some,118-120 but not all57 studies, and experimental 
investigations have suggested that increased betaine availability may reduce adiposity 
and improve insulin resistance.53 A recent Swedish study found robust, but relatively 
weak, associations between genetic traits coding for lower plasma DMG and increased 
risk of developing diabetes during long-term follow-up.94 Among a US male general 
population lower serum sarcosine levels were observed among those with than without 
T2D.121 
Higher dietary intakes of PC were related to increased risk of incident T2D,122 
and higher plasma TMAO levels have been observed among patients with than without 
T2D.120, 123 This potentially links choline intake and the gut microbiome to T2D risk, 
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and the relationship is possibly also modified by the inhibiting actions of insulin on 
FMO3.124   
Substantially higher urinary betaine levels have been observed among patients 
with T2D.57 Our group showed that urine betaine was highly correlated with urine 
DMG and sarcosine, and that urine betaine predicted new-onset diabetes within the 
WENBIT follow-up period;125 however, no longer-term prospective studies of urinary 
choline metabolites on incident T2D risk have hitherto been reported. 
1.3.8 OPEN RESEARCH QUESTIONS 
In summary, there are preclinical and epidemiological evidence of significant 
alterations in choline metabolism according to both CVD and T2D. However, most 
prospective epidemiological studies have so far focused on the CVD risk associated 
with systemic choline and betaine concentrations, in addition to circulating TMAO 
levels, and relatively little attention has been paid to relationships with DMG and 
sarcosine. Moreover, with the exception of betaine, any prospective relationships 
between choline metabolites in the urine and incident disease have yet to be 
investigated. There is therefore a need for a more comprehensive assessment of several 
choline metabolites in relation to CVD and T2D in large populations. 
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2 AIMS OF THE THESIS 
The primary goals of the project were to investigate the relationship between plasma 
DMG levels and risk of incident AMI and mortality, as well as exploring potential 
associations between circulating and urinary choline metabolites with incident T2D.  
Secondary aims were to investigate potential improvements in risk prediction and to 
assess temporal trends of the biomarkers investigated. 
SEPARATE PROJECT AIMS 
2.1 Paper I: To investigate the association between plasma DMG and incident AMI 
among patients with suspected SAP. 
2.2 Paper II: To explore the relationships between plasma DMG with all-cause, 
cardiovascular and non-cardiovascular mortality in two independent cohorts of 
patients with suspected SAP and AMI, respectively. 
2.3 Paper III: To study the associations between systemic and urinary choline 
metabolites with incident T2D among patients with suspected SAP. 
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3 MATERIALS AND METHODS 
3.1 PATIENT POPULATION 
3.1.1 THE WENBIT, NORVIT AND WECAC COHORTS 
The WENBIT (ClinicalTrials.gov Identifier: NCT00354081) and NORVIT 
(ClinicalTrials.gov Identifier: NCT00266487) were large, Norwegian, randomized, 
controlled trials initiated and carried out in the late 1990’s and early 2000’s to 
investigate the clinical effect of tHcy lowering therapy with folic acid + vitamin B12 
and/or vitamin B6 against placebo in a 2x2 factorial design. The WENBIT126 enrolled 
3090 patients from the Western Norway, the majority (98.6%) having 
angiographically verified significant CAD. The patients were recruited from 
Stavanger and Haukeland University Hospitals in Stavanger and Bergen, Norway. 
During the study enrollment from April 1999 to April 2004, both hospitals carried out 
percutaneous coronary intervention (PCI) whereas only Haukeland University 
Hospital carried out open heart surgery. The multicenter NORVIT127 studied 3749 
patients hospitalized for an AMI in all Norwegian health regions, and enrolled patients 
from December 1998 to March 2002. The patients in the NORVIT were recruited 
from both local, regional and university hospitals, and did not routinely undergo 
coronary angiography, as is recommended by current guidelines.128  
Participants in the NORVIT provided blood specimens at the baseline visit, and 
study visits after 1 year and at the end of study, whereas participants in the WENBIT 
provided blood samples at baseline, and at study visits after 1-3 months, 1 year and at 
the end of study. Most WENBIT study participants additionally provided urine 
samples at baseline and after 1 year of follow-up. 
During the WENBIT study enrollment period, 2119 patients who underwent 
cardiac catheterization at Haukeland University Hospital, but who were not enrolled in 
the WENBIT trial, were included in an extended cohort of patients. These patients 
provided baseline blood and urine samples, and were followed up according to clinical 
endpoints, but did not attend later study visits. Together with WENBIT participants, 
these patients totaled 5209 patients, and made up the Western Norway Coronary 
Angiography Cohort (WECAC) (Figure 3).  
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In the current work, we chose to focus on WECAC patients with suspected or 
verified SAP (n=4164), thereby excluding 1045 patients with other indications for 
angiography (ACS, n=519; valvular disease,  n=331; other indications, n=195). Our 
rationale was to study a rather homogenous group of patients, being less prone to 
changes in metabolites and biomarkers secondary to the acute phase (e.g. 
inflammation), as well as having less propensity to adapting life-style changes129 
which could potentially influence risk relationships between baseline values and 
outcome. Besides, WENBIT patients with ACS had their biosampling done partly 
before, during, or even after coronary angiography and intervention, without such 
information being registered in the database, making it possible that such procedures 
might have influenced biomarker status. 
A total of 42 WECAC patients with suspected SAP rejected extended follow-
up, and were thus censored in terms of endpoints beyond 31 Dec 2006. We did not 
have access to follow-up data on patients who moved out of Norway. 
3.1.2 FOLLOW-UP AND CLINICAL ENDPOINTS 
The WENBIT and the NORVIT cohorts were granted long-term follow-up on incident 
cardiovascular events, and all-cause, cardiovascular and non-cardiovascular mortality, 
extending the original trial durations. The rest of the patients making up the WECAC 
were granted inclusion in the combined WENBIT-NORVIT cohort after approval from 
the Regional Ethics Committee (Regional Ethics Approval number 2010/1880), which 
also approved the collection of information on incident diabetes from the CVDNOR 
project (Regional Ethics Approval number 2013/2324). The Regional Ethics 
Committee also specifically approved the projects included in the current work; “DMG 
og coronarsykdom” (Regional Ethics Approval number 2010/1881-8) and “Betaine 
and choline excretion in urine” (Regional Ethics Approval number 2010/1747-8).  
All endpoints were linked to each patient’s unique Norwegian 11-digit person 
identification number. Incident AMI (paper I) in the WECAC was classified according 
to American and European guidelines of 2000,130 but also included patients diagnosed 
with either “sudden cardiac death” or “sudden death” (ICD-10 codes I46 and R96, 
respectively),131 being in line with the definition used in previous Scandinavian 
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epidemiological surveys.132 Endpoint information was obtained from the 
WENOCARD and validated by the WENBIT endpoint committee as previously 
described.126 Procedure-related AMI was defined as those occurring within 24 hours 
after coronary revascularization, and were not included.  
Mortality data in both the NORVIT and the WECAC cohorts (paper II) were 
obtained from the Death Registry at Statistics Norway (http://www.ssb.no). The 
information on incident AMI and mortality, including time to events, was collected 
throughout 31 December 2006. 
Information on incident T2D was retrieved from the CVDNOR project, 
assessing public hospital discharge diagnoses ICD E110-E119 throughout 31 
December 2009. These latter endpoints were not validated further, nor did we obtain 
reliable time-to-event data. This was mainly because we had access to detailed 
hospitalization data for only a limited number of patients. Moreover, for the majority 
of cases (~90 %), T2D was recorded as a secondary diagnosis and not the main reason 
for contacting the health care system. 
3.1.3 LABORATORY ANALYSES 
Baseline study sampling was carried out usually 1-3 days prior to the angiographic 
procedure among patients enrolled at Haukeland university hospital, whereas patients 
recruited from Stavanger university hospital usually had their biosampling done at the 
day of cardiac catheterization. Plasma samples were immediately prepared and stored 
in tubes either containing ethylenediaminetetraacetic acid (EDTA) or sodium citrate, 
whereas serum samples were stored in gel-containing tubes. Baseline urine samples 
were collected by the patients at home on the morning of angiography. Biosampling at 
later study visits was carried out at as described above, and the patients were not 
instructed to fast. All biosamples were frozen at –80oC until thawed and analyzed by 
laboratory staff blinded to the clinical outcomes of the patients. The results from 




































































































































therefore we were not able to include this variable in papers I and II. 
Routine biochemical analyses were carried out by the local laboratories in each 
recruiting hospital of the WECAC and NORVIT cohorts. Estimated glomerular 
filtration rate (eGFR) was calculated according to the Chronic Kidney Disease 
Epidemiology Collaboration formula.133 Professor Rolf K. Berge and his research 
group at the University of Bergen analyzed serum apolipoprotein (apo) A1 and apo B 
100 on the Hitachi 917 and 912 systems (Roche Diagnostics, GmbH, Mannheim, 
Germany), respectively. Study specific blood and urinary analyses were carried out by 
Bevital As, Bergen, Norway (http://www.bevital.no), using automated methods based 
on mass spectrometry for investigating large numbers of samples, but requiring small 
individual sample volumes (Table 2).134 Urine choline metabolites were measured by a 
modified liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.135  
Table 2. Laboratory assays used for analyses of metabolites in 
plasma/serum and urine 
Metabolite Method 
Plasma 
choline LC-MS/MS135, 136 
betaine LC-MS/MS135, 136 
dimethylglycine LC-MS/MS135, 136 
trimethylamine-N-monoxide LC-MS/MS 
total homocysteine GC-MS137 
riboflavin LC-MS/MS138 
5’-pyridoxal phosphate LC-MS/MS138 
Serum 
sarcosine GC-MS134 
folate Microbiological assay139 






DMG indicates dimethylglycine; GC-MS/MS, gas chromatography mass 
spectrometry; LC-MS/MS, liquid chromatography-tandem mass spectrometry. 
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Serum in citrate tubes had to be used instead of EDTA plasma when assessing 
sarcosine status in blood, as the EDTA tubes already contained a significant amount of 
sarcosine.142 The Bevital laboratory also measured serum C-reactive protein (CRP) by 
an ultrasensitive immuno- matrix-assisted laser desorption/ionization (MALDI)-MS 
method, with a detection limit of 0.17 mg/L.143 Data on serum CRP, lipid fractions, 
plasma glucose and HbA1c were only available in the WECAC. 
The BHMT single nucleotide polymorphism (SNP) BHMT 742 G>A,144 as well 
as levels of glycated hemoglobin (HbA1c)145 were assessed from EDTA whole blood 
samples, using matrix-assisted laser desorption/ionization-time-of-flight (MALDI-
TOF) mass spectrometry.  
In a subset of 1343 WENBIT participants, of whom the majority were fasting, 
we also obtained baseline serum insulin and C-peptide from citrate samples, using a 
solid phase, two-site chemiluminescent immunometric assay (Immulite 2000) from 
Siemens Healthcare Diagnostics. However, since EDTA plasma is usually used for 
insulin measurements, and the amount of citrate within each tube slightly varied, we 
compared EDTA and citrate samples from 40 patients, and found that the insulin 
concentrations were highly correlated (Spearman’s rho 0.95; P<0.0001) (Figure 5); 
hence, the data obtained from citrate samples was extrapolated into those of EDTA 
plasma by linear mean regression modelling using a regression coefficient (β) of 
1.494. Among fasting, non-diabetic patients with valid insulin and plasma glucose 
measurements, we calculated the computer-based homeostatic model assessment 
(HOMA2)146 of insulin resistance, beta-cell function and insulin sensitivity. The 
HOMA2 parameters were used in articles II and III. 
We also obtained serum levels of high-sensitive cardiac troponin T (hs-cTnT) 
among 4070 patients with SAP in the WECAC, using a Modular E170 from Roche 
Diagnostics, with a lower detection limit of 3ng/l. This parameter was not yet available 
when writing article I, nor was it available among NORVIT patients. 
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Figure 5. The relationship between insulin in citrate plasma and serum. 
3.1.4 DATA ON DIETARY CHOLINE AND BETAINE INTAKE 
Among WENBIT participants, 2412 patients provided information on dietary intake of 
macro- and micronutrients by completing a food frequency questionnaire (FFQ).147 
The daily intakes of total energy, choline and betaine were estimated among 1939 
patients,148 after excluding those with either particularly low (men and women <3300 
kJ/day and <3000 kJ/day, respectively) or high (men and women >17500 kJ/day and > 
15 000 kJ/day, respectively) estimated energy intake. 
3.2 STATISTICAL METHODS 
3.2.1 SOFTWARE 
For all statistical analyses, we used SPSS for Windows versions 18-21 (SPSS Inc. 
Released 2009. PASW Statistics for Windows, Version 18.0. Chicago: SPSS Inc.; 
IBM Corp. Released 2010-2012. IBM SPSS Statistics for Windows, Version 19.0- 
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21.0. Armonk, NY: IBM Corp.), the free, open-source statistical software R for 
Windows versions 2.15.0-3.0.2 (The R Foundation for Statistical Computing, Vienna, 
Austria; packages nlmee, Hmisc, ppcor, mgcv, segmented, PredictABEL, and ICC) 
and SPSS Sample Power Version 2.0 (SPSS, Inc., 2000, Chicago, IL, www.spss.com). 
Graphics were obtained by the various R packages, and slightly modified according to 
the standards of each journal by using the free image editing software Inkscape for 
Windows version 0.48 (www.inkscape.org). 
3.2.2 BASELINE DATA 
In articles I and II we assessed potential linear relationships between plasma DMG 
quartiles (i.e. categories according to the 25th, 50th and 75th percentiles) and relevant 
clinical, anamnestic and biochemical parameters. Traditionally, linear associations 
between continuous variables have been explored by linear least squares mean 
regression models and analysis of variance (ANOVA) for continuous and categorical 
variables, respectively. However, treating the mean as an average measure is 
problematic, especially in terms of biological data, due to their often extensively right-
tailed (non-normal) distribution. In the case of least squares mean linear regression 
non-normal distribution may also severely influence the regression line.149 Most 
commonly, such right-skewed continuous data have been log-transformed before 
analyses, followed by reporting trends across groups according to their geometric 
means or back-transformed values. One problem is, however, that such values are 
quite arbitrary and do not communicate well with the reader. Moreover, regarding 
linear trends across ordinal categories, ANOVA modeling assumes that data are 
normally distributed within each group. One way around this problem could be to 
apply the non-parametric Kruskall-Wallis one-way of variance test. However, this 
method does not allow for adjusting for covariates.  Therefore, we used semi-
parametric quantile regression modeling, as provided by the R package Quantreg. 
Quantiles refer to the number of equally distributed parts of a cumulative distribution. 
In short, quantile regression does not imply assumptions regarding distributions, and 
allows for covariate adjustment. The method may explore linear trends between any 
quantile (i.e. percentile) of two continuous variables; however we focused on the 
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trends according to the median (50 percentile) in all three papers. Quantile regression 
was also utilized when assessing differences in continuous variables according to two 
groups (e.g. patients with or without T2D). However, in paper III, we explored the 
relationships between incident T2D and not only one, but all metabolites downstream 
the choline oxidation pathway. Thus, it was not feasible to carry out baseline trend 
analyses according to each one of the independent variables, but rather making an 
overview over various interrelationships between choline metabolites and other 
variables of interest (i.e. correlation matrix). Once again, we wanted to adjust the 
correlations for covariates and we had to overcome the problem of non-normal 
distributions, the latter violating the assumptions when carrying out Pearson’s 
correlations. We therefore solved this by performing partial ranked Spearman 
correlations, using the R package ppcor. 
For categorical and ordinal dependent variables, we performed trend analyses 
by binary or ordinal logistic regression models, respectively. 
3.2.3 ENDPOINT ANALYSES 
Time-to-event analyses, censoring and the problem of competing risks. For articles 
I and II the occurrence of AMI or death was well defined, also in terms of time to 
events, the latter being of importance when following patients for several years. 
Hence, we used the well-established method of Cox proportional hazard modeling, 
where we censored patients who did not experience an event during follow-up, or for 
whom such information was not available. However, censoring of patients is 
problematic, because it does not allow us the information on what may have happened 
to those patients afterwards. In addition, some endpoints may only occur once, for 
example death. This generates the problem of competing risks, where one endpoint 
changes the possibility of experiencing another. It has been stated that not properly 
accounting for competing risk may overestimate the risk association.150 Thus, in article 
II, we constructed subdistribution hazard regression models, using the R package 
crr,151 treating cardiovascular and non-cardiovascular death as competing events.  
Cox proportional hazards modeling is quite robust. However, the assumption of 
proportional hazards is crucial, and was assessed by inspecting log-log plots according 
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to categorical variables, and calculating and testing Schoenfeld residuals, the latter by 
using the cox.phz function in the R package survival. 
Endpoint data without information on time to event. Assessing the relationship 
between baseline and dichotomous endpoint data may also be carried out using binary 
logistic regression, preferably in analyses of endpoints with a pre-defined follow-up 
period (for example 30 day in-hospital mortality), or when exploring the relationship 
in studies without (reliable) information on time to events. We had prospective data on 
all end-points in our studies, but since T2D is not generally characterized by an abrupt 
onset of symptoms,33 we chose to assess risk associations by using binary logistic 
regression in article III.  
Subgroup analyses. The association between an independent and a dependent 
variable can differ between certain population groups, and may be assessed by 
performing analyses in each subgroup of interest. Random variation in associations 
between the independent and the dependent variable may occur across subgroups; 
therefore the potential effect modification should be tested formally. This is usually 
performed by including an interaction product term between the subgroup variable (the 
potential effect modifier) and the independent variable of interest in the model, and 
should also include the interaction term’s lower order components.152  
All subgroup analyses were carried out and reported according to current 
recommendations.153 Subgroups were obtained from predefined categories (e.g. 
gender, smoking status or study treatment), or created according to the median value 
of continuous variables, the latter to make the groups as equally sized as possible. We 
performed interaction analyses using the same methodology as described above, 
paying particularly attention to subgroups of established CHD risk factors and baseline 
status of biological parameters related to the choline oxidation pathway. The former 
may help identify subgroups in which a novel biomarker may have a more pronounced 
effect on risk prediction. The latter suggests metabolic mechanisms involved in 
associations between outcome and metabolite status, as differences in the latter may 
arise from alterations in the production, catabolism or tissue clearance of the 
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metabolite, or of their combination. 
Model discrimination and reclassification. Model discrimination was assessed by 
calculating the Harrells C-statistic, which equals the area under the receiver-operating 
curve (ROC-AUC; Figure 5). Broadly speaking, the C-statistic will provide a 
probability score between 0.5 and 1 on how well the model actually predicts patients 
with and without the outcome, with the former and latter values corresponding to a 
useless coin-toss and a perfect prediction, respectively.  
Figure 5. The area under the receiver-
operating curve.  
The diagonal line illustrates a model with 
no discriminative value; the brown area 
illustrates a model with intermediate 
discriminative predictive value; the green 
area (also covering the brown area) 
illustrates an optimal discriminative model. 
However, once a few strong and robust predictors are included in the model, the 
adding of new variables seldom provides any substantial improvement in the C-
statistic.154 Thus, other, more sensitive, measures of model discrimination and 
reclassification have been proposed, with the most notable and utilized being the 
integrated discrimination index (IDI) and the net reclassification improvement 
(NRI).154 The IDI can be defined as the difference in discrimination slopes between 
models with and without the biomarker(s) of interest; hence it compares the ability of 
models to discriminate cases from non-cases. The NRI will provide the percentage of 
patients that are being correctly reclassified to new risk categories, penalized by the 
percentage of patients that are wrongly reclassified. This estimation is performed both 
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for patients who do and do not experience an event. 
NRItotal = NRIevent + NRInon-event
When considering CVD naïve patients, such risk categories for cardiovascular 
mortality are typically divided according to 0-5%, 5-10%, 10-20% and above 20% of 
risk of the event within a certain period of time (usually 10 years), as illustrated by the 
Systematic Coronary Risk Evaluation Project (SCORE) promoted by the European 
Society of Cardiology.155 Allocation of patients into a particular risk category will 
potentially guide the clinician in the decision making of initiating certain preventive 
interventions. Therefore, the NRI may provide a more clinical useful metric than both 
the C-statistic and the IDI. However, among patients with known (atherosclerotic) 
CVD, no established risk categories exist, mostly because such patients generally 
receive quite similar medical treatment (i.e. a statin and aspirin) and life-style advise. 
In fact, it is advocated against creating new risk categories under conditions were none 
already exist.156 Hence, the category free, or continuous, NRI (NRI>0) may serve as a 
better measure of improvement in reclassification. The NRI>0 equals the net 
improvement in patients who are either being correctly up- or down-classified on a 
continuous (category-free) scale from 0 to 100%.156 Based upon the comparison with 
Cohen’s d, it has been suggested that small, medium and large effect sizes correspond 
to NRI>0 of <20%, ~40% and >60%, respectively.157 
3.2.4 REPEATED MEASUREMENTS 
Temporal changes in biomarker concentrations. As described earlier, not all 
WENBIT and NORVIT study patients attended each study visit beyond baseline, and 
there were also inequalities according to the time spans between sampling points. We 
could therefore not simply use the well-known and widely used repeated measures 
analysis of variance (rANOVA), or its derivatives, when analyzing longitudinal 
biomarker data. Instead, we used the more flexible method of mixed (-effects) linear 
regression modeling, provided by the R package nmle. As opposed to rANOVA, such 
modeling may include subjects with missing data points, and allows for uneven time-
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spans between study visits during follow-up. Moreover, rANOVA modelling requires 
homogeneous variances in the variables used, whereas in linear mixed modelling, such 
heterogeneity may be easily adjusted for. Finally, as opposed to the rANOVA method, 
there is no need for correcting for multiple testing when using the linear mixed 
modelling approach in the setting of more than one time interval.158 Data from all 
study visits in the WENBIT and NORVIT were used for the repeated measures 
analyses in paper I and II. In paper III we used the baseline and 1-year measurements 
in WENBIT, since urine sampling was only performed among a few on other study 
visits. Study treatment effects were explored by including an interaction product term 
between time and study treatment group in the model. 
Within-subject reproducibility. The coefficient of reliability (CoR) is also known as 
the one-way random effects intraclass coefficient (ICC) and according to Rosner159 it 
is defined as 
CoR = ICC = σα2/ (σα2 + σε2),  
where σα2 denotes the between-subject variance and σε2 the within-subject variance. 
Hence, a CoR (ICC) approximating 1 will imply very low within-subject variance. 
CoRs (ICCs) of 0.4-0.75 and ≥ 0.75 are considered fair to good, and excellent, 
respectively.159 In paper I and II we used linear mixed modelling when calculating 
crude CoRs; however in paper III we used the R package #ICC, which also provided a 
95% confidence interval together with the ICC estimate.  
3.3 THE STROBE GUIDELINES – ENHANCING TRANSPARENCY 
The vast majority of epidemiological studies stem from observational data. However, 
it is imperative that studies originating from observational data, as for any other 
sources for that matter, have transparent methodology in order to highlight strengths 
and weaknesses. The Strengthening the Reporting of Observational Studies in 
Epidemiology (STROBE) statement160 was launched in 2007 as a joint attempt from 
several authors and medical journals to improve such transparency. The statement 
46 
contains a checklist including information to be reported in an observational study, and 
has been widely endorsed by a number of scientific journals.161 The STROBE 
initiative has also been extended, and currently comprises specific guidelines on the 
reporting on several types of observational studies, including the STROBE: Molecular 
Epidemiology (STROBE-ME),162 which was applied in articles I-III. 
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4  SUMMARY OF THE RESULTS 
4.1 PLASMA DIMETHYLGLYCINE AND RISK OF INCIDENT ACUTE 
MYOCARDIAL INFARCTION IN PATIENTS WITH STABLE ANGINA 
PECTORIS (PAPER I) 
Arterioscler Thromb Vasc Biol. 2013;33:2041-8 
Among the 4156 eligible patients with SAP, 72.0% were men and the median (5-95 
percentiles) age was 62 (44-78) years. About 1/3 were active smokers, approximately 
half had hypertension, 40.3% had experienced a previous AMI and 11.8% had self-
reported diabetes. Median (5-95 percentiles) plasma DMG was 4.1 (2.6-7.3) μmol/L. 
Plasma DMG levels were higher among non-fasting patients, and positively related to 
male gender, current smoking, higher age, hypertension, previous CVD, CRP, the use 
of beta-blockers and ACEI and/or ARBs, and circulating levels of most one-carbon 
and choline metabolites, as well as to plasma methylmalonic acid (MMA). Plasma 
DMG was inversely related to eGFR, serum total cholesterol and apo A1, in addition 
to the BHMT 742 G>A minor A allele. 
During a median (5-95 percentiles) follow-up time of 4.6 (1.6-6.8) years, 343 
(8.3%) of the patients experienced an AMI, and the incidence was positively related to 
increasing plasma DMG quartiles (P for log-rank < 0.001). In crude Cox regression 
models, the HR (95% CI) for AMI was 2.43 (1.78-3.31; P<0.001) when comparing the 
4th vs. the 1st DMG quartiles. Adjusting for age, gender and fasting status somewhat 
attenuated the risk estimate (HR (95% CI) 1.95 (1.42-2.68); P<0.001), but further 
adjustment for serum apo A1 and apo B100, diabetes, smoking, and hypertension had 
only minor influence on the risk associations. Particular strong relationships between 
plasma DMG and risk of AMI were observed among non-smokers and patients with 
serum triglycerides or apoB100 < median (P for interaction ≤ 0.03). 
Adding plasma DMG to the multivariate model improved model discrimination 
(∆C-statistic (95%CI) 0.012 (0.001-0.022); P=0.04), and improved reclassification. 
In WENBIT patients we observed increasing plasma DMG throughout the study 
for the group as a whole, but not among patients receiving folic acid + vitamin B12 
(with or without vitamin B6). Among patients randomized to placebo treatment, the 
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CoR for plasma DMG was 0.93 and slightly lower when the variable was log-
transformed. 
We did not report on the association between plasma DMG and incident AMI in 
NORVIT; however, when carrying out such analyses in retrospect, we observed a 
positive association between plasma DMG and AMI also in this cohort, although the 
relationship was somewhat weaker (Table 3). The association were similar when 
adjusting for plasma tHcy (HR [95% CI] for the 4th vs. 1st quartile 1.25 [1.00-1.56]; 
P=0.05), but attenuated when accounting for eGFR, serum total cholesterol, smoking, 
diabetes and hypertension (HR [95% CI] 1.14 [0.90-1.43]; P=0.28). 
 
Table 3. The relationship between plasma dimethylglycine and incident acute myocardial 
infarction among patients in the Norwegian Vitamin Trial, n=3733 
 Unadjusted  Adjusted for age and gender 
 HR (95% CI) P  HR (95% CI) P 
Plasma DMG, quartiles      
 1 Ref   Ref  
 2 1.07 (0.85-1.35) 0.55  1.02 (0.81-1.28) 0.87 
 3 1.20 (0.96-1.49) 0.11  1.06 (0.85-1.33) 0.61 
 4 1.61 (1.30-1.98) <0.001  1.30 (1.04-1.61) 0.02 






4.2 ELEVATED PLASMA DIMETHYLGLYCINE IS A RISK MARKER OF 
MORTALITY IN PATINTS WITH CORONARY HEART DISEASE (PAPER II) 
Eur J Prev Cardiol. 2015;22(6):743-52 
The 4150 patients with SAP eligible from the WECAC were generally similar to those 
included in paper I; hence baseline characteristics and the relationships between 
baseline plasma DMG and various clinical and biochemical parameters did also not 
differ to any particular degree from those reported in the previous chapter. In addition, 
we observed a strong positive relationship between plasma DMG and serum hs-cTnT, 
and inverse associations between plasma DMG and indices of insulin sensitivity. 
The 3733 eligible patients with AMI from the NORVIT cohort had median (5-
95 percentiles) age of 63 (44-81) years, and 73.9% were males. As compared to SAP 
patients, the NORVIT participants were older, more often smokers and had lower 
eGFR, but had less often preexisting CVD, hypertension or diabetes.  
Among patients with AMI baseline plasma DMG was positively related to male 
gender, age, current smoking, hypertension, serum creatinine, previous CVD, plasma 
choline and one-carbon metabolites, and the use of beta-blockers and ACEIs and/or 
ARBs. Plasma DMG was negatively related to eGFR, plasma riboflavin, serum folate 
and the BHMT 742 G>A minor A allele. 
Median (5-95 percentiles) follow-up times were 4.7 (2.8-6.8) and 7.0 (1.1-8.8) 
years among SAP and AMI patients respectively. Among SAP patients, 308 (7.4%) 
died, whereas 772 (20.7%) of the patients with AMI died. In both cohorts, the risk of 
all-cause mortality was positively related to increasing plasma DMG quartiles (P for 
log-rank<0.001). When comparing the 4th to the 1st DMG quartiles, the crude HRs 
(95% CI) for all-cause death were 2.52 (1.78-3.57); P<0.001 and 2.80 (2.27-3.44); 
P<0.001 among patients with SAP and AMI, respectively. Adjusting for age and 
gender attenuated the risk estimates (1.72 (1.21-2.46) and 1.76 (1.42-2.18)); however, 
the associations were essentially unaltered in the multivariate models. Plasma DMG 
was more pronouncedly associated with cardiovascular than non-cardiovascular death, 
and similar results were obtained when performing competing risk analyses. 
Subgroup analyses showed trends towards stronger risk associations between 
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plasma DMG and all-cause and cardiovascular mortality among SAP patients with 
serum TG or apoB100 < median. 
Adding plasma DMG to the multivariate model improved or trended to improve 
model discrimination and reclassification for all-cause and cardiovascular mortality, 
particularly among patients with AMI. 
Similar to what was observed in article I, AMI patients who were randomized to 
either placebo or treatment with vitamin B6 alone experienced a rise in plasma DMG 
during follow-up; however no changes in plasma DMG were observed for patients 
receiving folic acid + vitamin B12 (with or without vitamin B6). The CoR for plasma 
DMG among AMI patients allocated to placebo was 0.72. 
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4.3 THE PROSPECTIVE ASSOCIATIONS OF SYSTEMIC AND URINARY 
CHOLINE METABOLITES WITH INCIDENT TYPE 2 DIABETES (PAPER III) 
Submitted, January 2016. 
For baseline analyses, 4070 SAP patients were eligible, of whom 71.9% were men, 
and the median (25-75 percentiles) age was 62 (55-70) years. Patients with T2D 
(n=449 (11.0%)) had higher plasma choline and TMAO, lower plasma betaine and 
serum sarcosine, and higher urine choline, betaine, DMG and sarcosine than 
nondiabetic patients. Higher plasma choline and serum sarcosine, and lower plasma 
betaine concentrations were correlated with a generally more adverse T2D risk profile. 
Plasma DMG was positively related to indices of insulin resistance and CRP. Plasma 
TMAO was positively related to indices of insulin resistance and plasma choline, 
plasma DMG and serum sarcosine. Most choline metabolites in urine were positively 
related to an adverse risk profile of T2D.  
The levels of all metabolites, except for urine betaine, increased during 1 year 
of follow-up among WENBIT patients allocated to placebo treatment. Treatment with 
folic acid + vitamin B12 (with or without vitamin B6) augmented the increase in 
plasma choline and betaine, whereas plasma and urine DMG and urine sarcosine were 
lowered, when compared to placebo. Vitamin B6 alone, on the other hand, increased 
plasma DMG, but dampened the increase in serum sarcosine and urine choline, as 
compared to placebo treatment. We did not observe any temporal alterations in overall 
plasma TMAO, also according to WENBIT study treatment. 
A total of 3261 patients without registered T2D at baseline were followed for 
median (25-75 percentiles) 7.5 (6.4, 8.7) years, during which 233 (6.4%) patients were 
registered with incident T2D. As compared to those who did not develop T2D, patients 
who did develop T2D had lower baseline plasma betaine, whereas urine betaine and 
sarcosine were higher. In univariate logistic regression models, plasma betaine was 
inversely, while urine betaine, DMG and sarcosine levels were positively associated 
with incident T2D (ORs per 1 SD (95%I) 0.78 (0.69-0.89), 1.27 (1.11-1.45), 1.23 
(1.07-1.42), and 1.31 (1.14-1.50), respectively). Adjusting for potential confounders 
and other T2D risk factors only slightly altered the risk estimates. We also performed a 
stepwise backwards elimination logistic regression, including all choline metabolites 
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being associated with incident T2D in univariate analyses. The selection was 
determined by the Akaikes’ information criterion, and left only plasma betaine and 
urine sarcosine of the choline metabolites in the final model. When including plasma 
betaine or urine sarcosine, the multivariate model discrimination improved, as did the 
reclassification of patients according to the NRI>0. 
The ICCs (95% CIs) for plasma betaine and urine sarcosine among patients 
randomized to placebo were 0.62 (0.56-0.66) and 0.69 (0.64-0.74), respectively. 
Similar ICCs were obtained among patients receiving vitamin B6 only treatment, 
whereas treatment with folic acid + vitamin B12 (with or without vitamin B6) 
weakened the test-retest reliability for both metabolites. 
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5 DISCUSSION 
5.1  SUMMARY 
The current thesis is based on data from either or both of two independent cohorts of 
patients with suspected or verified CHD, and the aims were to investigate the 
associations between plasma DMG and risk of incident AMI and mortality, the 
relationships between choline metabolites and incident T2D, any improvement in 
model risk prediction and reclassification for relevant biomarkers, and temporal trends 
in choline metabolites according to B-vitamin intervention. 
The studies show that plasma DMG is a predictor of incident AMI among 
patients with suspected SAP, and predicts all-cause and cardiovascular mortality 
among patients with both stable and unstable CHD. We also report that lower plasma 
betaine and higher urine betaine, DMG and sarcosine are associated with new-onset 
T2D among patients with SAP. Once adjusted for age, gender and fasting status, all 
associations were essentially independent of traditional risk factors and potential 
confounders. Moreover, plasma DMG, as well as plasma betaine and urine sarcosine, 
may improve risk prediction of the respective endpoints. We also extend previous 
preclinical studies, by showing that treatment with high-dose B-vitamins influences 
the concentration of several choline metabolites in blood and urine. 
5.2  METHODOLOGICAL CONSIDERATIONS 
5.2.1  BIAS 
The term “bias” refers to a systematic flaw in study design, and comprises a number of 
potential errors in obtaining the data on which a study is based.163  
Selection bias. Selection bias concerns the selection of participants included in the 
study, thereby influencing the generalizability of the results. Since SAP is often 
diagnosed and treated without diagnostic angiography, the WECAC population may 
be regarded as a selected group and could possibly be at different risk of adverse 
events than SAP patients not admitted for angiography. However, once admitted to 
tertiary centres for diagnostic evaluation, the vast majority of SAP patients (both with 
and without angiographically verified CAD) were included in the WECAC during the 
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recruiting period, thereby strengthening the generalizability of the study results, as 
compared to only investigating WENBIT participants.  
We did not have information on hospitalized AMI patients who were not 
included in the NORVIT; however, the applicability of the NORVIT data for patients 
hospitalized with AMI in general is strengthened by the nation-wide multi-centre study 
design, including primary, secondary and tertiary hospitals. 
Most patients in both cohorts had information on systemic levels of choline, 
betaine and DMG; however, data on serum sarcosine and urine choline metabolites 
were only available in subpopulations of the WECAC. Thus, a selection bias by 
excluding patients with missing data was not likely in papers I-II, but may have been 
present in paper III, although the large study size probably attenuated any such effect. 
This problem could be assessed by further investigating potential differences between 
included and excluded patients, and in hindsight I admit that it would have been 
prudent to do so. On the other hand, when performing multivariate analyses in paper 
II, we used the statistical technique of multiple imputations to also include patients 
with one or more missing covariates. This did not lead to any alterations in the results, 
suggesting that excluding a relatively small number of patients was less likely to 
confer any serious selection bias. 
Repeated measurements were not undertaken in WECAC patients not included 
in the WENBIT. It is, however, unlikely that WENBIT study treatment would have 
affected biomarker status otherwise among these patients, as only minor differences in 
baseline choline metabolites levels were observed among participants and non-
participants in WENBIT among the entire cohort for SAP patients in WECAC (Table 
4). Yet, we cannot exclude that WENBIT study treatment may have influenced the risk 
estimates, although such treatment did not statistically significantly alter the results in 
survival analyses in relatively small groups. In addition, the WENBIT did not 
randomize patients in strata of clinical presentation; hence the subgroup of SAP 
patients were most likely not allocated to study treatment in a truly randomized 
fashion. It would therefore have been more appropriate to investigate not only the 
temporal trends in choline metabolites according to study treatment, but also to 
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Table 4. Baseline characteristics among patients in the Western Norwegian Coronary 
Angiography Cohort according to enrolment into the Western Norwegian B-vitamin 
Intervention Trial 
WECAC SAP patients 
Not WENBIT WENBIT P* 
Male gender, n (%) 946 (59.5) 2050 (79.7) <0.001 
Age, years 62 (55-69) 62 (54-70) 0.59 
Current smoking, n (%) 497 (31.2) 823 (32.0) 0.64 
Diabetes, n (%) 190 (11.9) 306 (11.9) 1.00 
Hypertension, n (%) 731 (45.9) 1215 (47.2) 0.44 
Previous CVD, n (%) 755 (47.5) 1648 (64.0) <0.001 
BMI, kg/m2 26.0 (23.7-28.7) 26.5 (24.5-29.0) <0.001 
HbA1c, % 6.4 (5.8-7.1) 5.8 (5.1-6.6) <0.001 
Plasma glucose, mmol/L 5.6 (5.0-6.6) 5.6 (5.1-6.6) 0.45 
eGFR,  88 (74-98) 92 (82-100) <0.001 
CRP, mg/L 1.83 (0.92-4.00) 1.74 (0.85-3.42) 0.002 
Lipid parameters 
total cholesterol, mmol/L 5.0 (4.3-5.8) 4.9 (4.2-5.7) 0.04 
LDL cholesterol, mmol/L 3.0 (2.4-3.8) 2.9 (2.4-3.6) 0.001 
HDL cholesterol, mmol/L 1.30 (1.03-1.60) 1.20 (1.00-1.42) <0.001 
triglycerides, mmol/L 1.42 (1.04-2.04) 1.55 (1.10-2.20) <0.001 
apo A1, mg/dL 1.36 (1.19-1.55) 1.26 (1.10-1.43) <0.001 
apo B100, mg/dL 0.90 (0.75-1.08) 0.85 (0.71-1.02) <0.001 
Extent of CAD at angiography <0.001 
0-vessel disease 764 (48.0) 282 (11.0) 
1-vessel disease 236 (14.8) 730 (28.4) 
2-vessel disease 241 (15.1) 687 (26.7) 
3-vessel disease 350 (22.0) 874 (34.0) 
Systemic one-carbon and choline metabolites, μmol/L 
tHcy 10.8 (8.9-13.2) 10.3 (8.6-12.3) <0.001 
tMet 27.7 (23.5-33.1) 25.9 (21.9-31.2) <0.001 
choline 10.0 (8.5-11.8) 9.5 (8.1-11.2) <0.001 
betaine 39.4 (32.1-48.1) 38.9 (32.0-47.5) 0.32 
dimethylglycine 4.4 (3.6-5.4) 4.0 (3.3-4.8) <0.001 
sarcosine 1.5 (1.2-1.8) 1.5 (1.2-1.8) 0.10 
Urine choline metabolites, mmol/mol creatinine 
choline 2.30 (1.71-3.17) 1.88 (1.38-2.55) <0.001 
betaine 7.84 (4.99-13.32) 7.28 (4.75-12.73) 0.02 
dimethylglycine 3.14 (1.93-5.05) 3.25 (2.13-5.07) 0.04 
sarcosine 0.13 (0.08-0.21) 0.14 (0.09-0.22) 0.008 
B-vitamers 
riboflavin, nmol/L 11.7 (7.3-19.7) 11.0 (7.6-17.4) 0.07 
folate, nmol/L  10.5 (7.8-15.6) 9.9 (7.3-14.5) <0.001 
cobalamin, pmol/L 433 (336-552) 337 (258-426) <0.001 
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PLP, nmol/L 43.8 (30.8-66.2) 40.0 (29.1-56.0) <0.001 
Medications prior to the baseline visit, n (%) 
beta-blocker 1102 (69.3) 1955 (76.0) <0.001 
statin 995 (62.6) 2029 (78.9) <0.001 
aspirin 1189 (74.7) 2157 (83.8) <0.001 
ACEI and/or ARB 1102 (69.3) 1955 (76.0) <0.001 
Medications at discharge, n (%) 
beta-blocker 1010 (63.5) 2005 (77.9) <0.001 
statin 1054 (66.2) 2281 (88.7) <0.001 
aspirin 1083 (68.1) 2317 (90.1) <0.001 
ACEI and/or ARB 501 (31.5) 829 (32.2) 0.65 
Clinical endpoints, n (%) 
AMI 132 (8.3) 212 (8.2) 0.99 
mortality 153 (9.6) 156 (6.1) <0.001 
T2D† 67 (4.8) 168 (7.4) 0.002 
ACEI indicates angiotensin converting enzyme inhibitor; AMI, acute myocardial infarction; ARB, 
angiotensin receptor blocker; BMI, body mass index; CAD, coronary artery disease; CRP, C-
reactive protein; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL, 
high-density lipoprotein; LDL, low-density lipoprotein; apo, apolipoprotein; PLP, pyridoxal 5’-
phosphate;tHcy, total homocysteine; tMet, total methionine which is the sum of methionine and 
methionine sulfoxide; T2D, type 2 diabetes. 
*Kruskal-Wallis test for continuous and Chi square test for categorical variables
baseline biomarker status. On the other hand, such interaction analyses would 
certainly decrease statistical power. 
Information bias. Overall, only a handful of patients in the WECAC and NORVIT 
withdrew their consent of long-term follow-up, making the proportion of patients lost 
to follow-up very low. Since we assessed the risk relationships between baseline 
choline metabolite status and the clinical endpoints, the primary aims of our studies 
were not vulnerable to further non-response from the participants. Moreover, the use 
of mixed linear modelling strengthened the validity of repeated-measures analyses, 
since data from patients not attending all study visits could be included. 
We cannot rule out the possibility that some WECAC patients experienced an 
incident AMI outside the Western Norway Health region, thereby leading to 
misclassification of non-cases in paper I. Also, some cases of AMI may have been 
undiagnosed or not reported properly. On the other hand, it is not likely that risk 
associations should differ in such subjects as compared to those with endpoints 
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registered in the WENOCARD, thereby reducing the risk of bias. Incident AMI in 
paper I was defined according to the revised European Society of Cardiology criteria 
from 2000,130 but also included sudden cardiac death (ICD-10 code I461) or other 
sudden unexplained death outside hospital (ICD-10 code R96)), being in line with 
definitions used in epidemiological surveys in Sweden and Denmark.132 Widening the 
definition of AMI as compared to a more stringent one including only ICD-10 codes 
I21-22 may thus have increased sensitivity but decreased the specificity of the 
endpoints in paper I.  
Using the nation-wide Cause of Death Registry, the risk association observed 
between plasma DMG and the hard endpoint all-cause mortality in paper II was not 
prone to either misclassification or detection bias. We were not able to validate the 
classification of mortality due to cardiovascular or non-cardiovascular causes, and the 
reliability of such classifications has indeed been questioned,164 although the stronger 
risk association between DMG and cardiovascular mortality strongly agrees with the 
results in paper I. 
The risk relationships between choline metabolites and incident T2D in paper 
III certainly pose the greatest concerns regarding detection bias in the current thesis. 
First, many patients with T2D are not diagnosed at all.23 Second, the diagnosis of 
incident T2D was dependent on discharge records from most, but not all, Norwegian 
public hospitals. It is plausible that patients with new-onset T2D, and being 
hospitalized, may have differed in several aspects from non-hospitalized or non-
diagnosed cases. Third, we were not able to validate the T2D diagnoses for each 
patient. However, when only looking at WENBIT participants during the in-trial 
follow-up, similar risk estimates between choline metabolites and T2D were 
obtained as those for the whole study population during long-term follow-up. Since 
the WENBIT participants were closely monitored by interview, as well as clinical 
and biochemical assessment, it is not likely that the results in paper III are flawed 
due to detection bias.  
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Regression-dilution bias. Risk associations between once-only assessed biomarker 
status and the clinical endpoint are inclined to be influenced by errors concerning the 
risk marker assessment per se, including measurement flaws, as well as the short- and 
long-term variation in biomarker status within each study participant – the latter 
collectively termed “within-person reproducibility”. This error is coined the 
“regression-dilution bias”, because all measurements will tend to regress to less 
extreme values when performed repeatedly. Consequently one-time assessment 
biomarker assessment will underestimate (i.e. dilute) the true effect.165 There have 
been several suggestions on how to overcome this problem, with perhaps the simplest 
solution being to directly correct the risk estimates for the ICC in a non-parametric 
manner (i.e. the corrected association equals the risk estimate/ICC).166 It follows that 
when the ICC is relatively low, the real risk estimate will be proportionally higher, 
whereas a high ICC implies a low degree of within-person variability and a 
proportionately low chance of regression-dilution bias. From a clinical point of view, 
however, a biomarker not requiring validation (i.e. having a high ICC) will surely be 
the more useful.  
In the current studies plasma DMG (paper I and II) and betaine (paper III), as 
well as urine sarcosine (paper III), had ICCs ranging from “good” to “excellent”, and 
comparing to ICCs reported for various other CHD biomarkers, such as serum total 
cholesterol (0.75) and serum CRP (0.54).167 Similar ICCs to our findings have been 
reported for plasma betaine and DMG in other populations, and seem consistent across 
genders and different ethnical groups.168 However, a somewhat lower ICC was 
reported for plasma DMG in the Nurses’ Health Study169 and Lever et al observed 
ICCs over 8 weeks for plasma betaine and DMG of only 0.43 and 0.15, respectively, 
when investigating a small population of healthy young men.170 No studies have 
hitherto reported on the ICC of urine sarcosine, but high ICCs for the highly correlated 
urine betaine and DMG have been described.170 
In all, our findings imply a relatively low risk of regression-dilution bias, 
favouring the use of the studies metabolites as clinical biomarkers. 
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5.2.2 CONFOUNDING 
For a given risk association confounding factors may be defined, quoting Miettinen 
and Cook, as “extraneous factors that might be explanatory, partially or totally, of the 
magnitude of the estimate of the effect”.171 Opposite to randomized clinical trials 
(RCTs), associations from observational studies are prone to confounding; hence, it is 
not possible to conclude on causal inferences. We can try to minimize this problem by 
adjusting the statistical models for potential confounders; however residual 
confounding will essentially always be present, as we are not able to identify or obtain 
data on all possible confounding variables.  
There exist no firm guidelines regarding selection of the most appropriate 
covariates in statistical models. In general, statistical textbooks advice against solely 
relying on stepwise inclusion or exclusion procedures based on statistical measures 
alone, but advocate the inclusion of biological sound covariates, as well. Baseline 
choline metabolites had statistically significant relationships with several other clinical 
and laboratory parameters, which could indeed serve as potential confounders. 
However, we chose not to adjust for all of them due to several reasons: First, including 
too many variables will inflate the regression model, attenuating power and making 
the estimate(s) less reliable (i.e. increasing the confidence interval(s)). Second, several 
parameters may be highly correlated, (for example urinary choline metabolites in 
paper III), or they may be redundant (for example the inclusion of serum LDL 
cholesterol, when serum total cholesterol is already in the model), introducing the 
problems of collinearity and singularity, respectively. A similar issue may arise when 
including variables that might reflect common biological mechanisms, as discussed 
with serum creatinine and plasma DMG in paper II, potentially leading to over 
adjustment.172 On the other hand, the weakening of a risk estimate when adjusting for 
a covariate might also suggest pathophysiological mechanisms relevant for the risk 
associations. We did not, however, assess these issues formally.173 Third, it is difficult, 
if not impossible, to compare the performance of models not containing the same 
covariates. In CHD studies, it is usual to adjust for established Framingham risk 
factors, although, strictly speaking, these are extensively validated for CHD naïve 
patients only. Therefore, we chose to primarily adjust for such factors in paper I and II; 
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accordingly we adjusted for several traditional T2D risk factors and biological 
plausible confounders in paper III. In papers I and II, we created extended multivariate 
models, further adjusting for variables with biological plausible (as well as statistical) 
relationships with DMG, in order to address potential pathophysiological pathways. 
This was also done regarding the associations between choline metabolites and 
incident T2D in paper III, although they were not reported due to space limitations. 
5.2.3 REVERSE CAUSALITY 
This term refers to the situation where the disease itself has influenced biomarker 
status, potentially impacting the real risk relationship. For example, the estimated daily 
energy intake among patients with T2D in the WECAC was not different from that of 
patients without diabetes, although the former had significantly higher BMI. This 
could be due to under-reporting among T2D patients, but also because these patients 
had reduced their energy intake as a consequence of their disease. If we were to 
explore the risk relationship between BMI and T2D, this would surely attenuate the 
true association.  
Reverse causality especially poses a problem in retrospective studies; hence our 
prospective study design is less prone to this error. Yet, a large proportion of the 
WECAC and NORVIT patients had established CVD, and we cannot exclude that the 
disease itself, its complications and/or medical therapy and lifestyle interventions 
somehow may have influenced plasma DMG levels. This is, however, not immediately 
supported by studies performed in other populations, reporting similar circulating 
DMG concentrations as those presented for the WECAC and NORVIT cohorts (Table 
5). Also, the risk estimates in paper I were similar when excluding patients without 
significant CAD at angiography, indicating that reverse causality might not pose a 
serious limitation. In paper III the risk estimates were similar when excluding patients 
with possible, yet not diagnosed T2D. Nonetheless, patients identified with higher 
baseline risk of T2D by conventional measures may also have had life-style or other 
















































































































































































































































































































































































































































































































































































































































































































































5.2.4 MENDELIAN RANDOMIZATION – IMPROVING THE SHORTCOMINGS 
OF OBSERVATIONAL STUDIES? 
One way of omitting the potential pitfalls of residual confounding, reverse causality 
and certain types of bias is to carry out so-called Mendelian randomization studies.178 
Such studies investigate whether inborn genetic traits affecting biomarker status also 
are associated with clinical outcomes, thereby bypassing the influence of potential 
environmental factors. In other words, the subjects investigated are randomized 
genetically already before they are born. In the era of ‘big data’ Mendelian 
randomization studies have been widely embraced, and questioned previously 
proposed causal relationships for several CHD biomarkers, such as CRP,179 HDL-
cholesterol180 and tHcy.108  
As previously mentioned, genetic traits of both BHMT and DDH predict plasma 
DMG levels, and a proper conducted Mendelian randomization study using the BHMT 
742 G>A data from the largely homogenous WECAC and the NORVIT populations 
could potentially shed more light on any causal relationship between DMG and 
adverse cardiovascular prognosis. We did, however, carry out logistic regression 
analyses, which did not indicate any relationships between the BHMT 742 G>A SNP 
and CVD or mortality risk in both articles I and II (Appendix I, Supplemental Tables 
IX and X; Appendix II, Supplemental Tables 10-15). This observation strengthens the 
assumption that elevated plasma DMG is not a causal risk factor for CVD per se. 
Mendelian randomization studies are, however, not free of assumptions, and 
pose several important shortcomings. These include, but are not limited to, genetic 
pleiotropy, linkage disequilibrium and issues of statistical power, as discussed in the 
review by Hansen et al:181 Probably the most important limitation is pleiotropy, 
meaning that genetic traits may have effects other than those only captured by 
measuring immediate biomarker levels. Such effects have not, to my knowledge, been 
investigated for the BHMT 742 G>A SNP; however it has been reported that the SNP 
does not statistically significantly predict plasma tHcy,182 nor did we find any 
differences in either plasma tHcy, betaine or total methionine levels according to this 
SNP in neither the WECAC or the NORVIT populations (Table 6).
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Allele frequencies were assessed according to the Hardy-Weinberg equation. 
The BHMT 742 G>A SNP was in Hardy-Weinberg equilibrium in the WECAC, but 
not in the NORVIT cohort. In the WECAC, we observed an approximately 5% 
decrease of plasma DMG per A allele (Table 4), whereas a decrease in plasma DMG 
only was observed among homozygotes for the variant allele in the NORVIT.   
There was a low minor A frequency, and as we showed in paper I, the impact of 
the A allele on the endpoint therefore had to be very high if we should have been able 
to obtain a statistically significant relationship between the genotype and disease risk. 
This illustrates the problem of insufficient statistical power. In the case of genetic risk 
associations, this usually necessitates the use of large population samples, as the 
effects brought about by single genetic traits usually are quite small, being particularly 
relevant for multifactorial diseases, such as CVD.  
5.2.5 GENERALIZABILITY 
As discussed in section 5.2.1.1, the current study populations are considered fairly 
representative of hospital-admitted patients with suspected or verified stable and 
unstable CHD in present-day Norway. On the other hand, our study subjects were 
mainly middle-aged to elderly white men, making it not straightforward to extrapolate 
the results to populations including healthy individuals, as well as those with other 
age, gender and ethnic characteristics.  
5.2.6 MULTIPLE COMPARISONS  
The current work includes a large number of statistical analyses. The P-value tells us 
the probability of falsely rejecting the null-hypothesis on the basis of a proper 
statistical test (i.e. Type I error). By setting the significance level (α) at 0.05, an 
average of 1 in 20 comparisons will thus lead to a statistically significant finding just 
by chance alone. Consequently, the probability of making such a Type I error is high, 
even when performing a relatively low number of individual tests,183 and statistical 
textbooks advice against drawing conclusions without adjusting for multiple 
comparisons. The most commonly used correction is the one proposed by the Italian 
mathematician Carl Emilio Bonferroni, where α = 0.05/m, and m denotes the number 
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of hypotheses being tested. On the other hand, the Bonferroni correction is a very 
conservative adjustment, especially when a large number of correlating parameters are 
being assessed.149 Also, some authors emphasize less on formal correction for multiple 
testing in post-hoc analyses in general, because observational research cannot be 
confirmative and must be considered hypothesis generating.183 Although it could have 
been more prudent to have applied other, less conservative, correction methods,149 we 
chose not to correct for multiple testing, which may pose a limitation on the 
interpretation of our results. When using mixed linear regression models, the problem 
of multiple comparisons was, at least to some extent, attenuated. 
5.2.7 SUBGROUP ANALYSES 
Post-hoc subgroup analyses always carry the potential of spurious findings. One of the 
most well-known examples is probably the one reported for the International Study of 
Infarct Survival (ISIS)-2 trial, where effects of study treatment were shown to 
significantly differ according to the astrological assignment of the patients.184 All post-
hoc (subgroup) analyses must therefore be considered hypothesis-generating only. 
This is particularly stressed in observational studies, where some authors actually have 
advocated against using formal statistical testing between and within subgroups at 
all.185 Nonetheless, although being considered at the lower level of scientific 
methodological hierarchy, unexpected findings from observational studies have made 
huge impact on medical sciences, reminding us not to dismiss them on a default basis. 
For example, hardly anyone would reject the observations of the effect from Penicillin 
fungi on bacterial growth, just because they resulted from untidiness in Sir Alexander 
Flemming’s research laboratory.186 The crux is that observational findings must be 
further validated.187  
Investigating treatment effects according to subgroups may help focusing on 
patient populations gaining the most benefit from treatment, and could also identify 
patients who even may be harmed from a particular intervention. Consequently, this 
has the potential to improve the clinical applicability of results from RCTs, which tend 
to generalize treatment effects. These issues are also highly relevant for diagnosis and 
risk assessment in CHD, as has been shown for the use of serum cardiac troponins and 
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electrocardiograms among patients with suspected ACS,188 to mention but a few. 
Notably, in the current growing era of personalized medicine it has been called for an 
even more advanced profiling of patients in terms of CVD risk, in order to further 
improve patient care and to cut costs.189  
Apart from their potentially immediate clinical utility, subgroup analyses in 
observational biomarker studies may also help elucidate novel pathophysiological 
mechanisms in an otherwise extremely complex system of biological pathways. This 
issue will be dealt with in more detail in later sections of the thesis. 
In paper I, we found trends towards stronger associations between DMG and 
adverse prognosis among non-smokers as compared to smokers in WECAC patients; 
however, there were no signs of any effect modification by smoking in the NORVIT in 
paper II. Although having relatively similar baseline characteristics, including plasma 
DMG status, the NORVIT population had a substantially larger proportion of current 
smokers (paper II). One reason for the lack of any interaction by smoking in the 
NORVIT could therefore be that more patients may have quitted smoking after having 
experienced an AMI, thereby diluting any interaction effect. On the other hand, 
median plasma levels of cotinine, a nicotine metabolite, actually increased throughout 
follow-up in the NORVIT (data not shown). Although patients might have been less 
likely to be smoking while being hospitalized, this indicates a low level of smoking 
cessation, although persistent cotinine levels could also be due to the substitution of 
combustible tobacco for nicotine replacement products or smokeless tobacco.   
The subgroup findings according to lipid parameters will be dealt with in more 
detail in section 5.4.2. 
5.2.8 MODEL DISCRIMINATION AND RECLASSIFICATION 
We showed that plasma DMG may improve the risk assessment of AMI and mortality, 
and that plasma betaine and urine sarcosine may aid in the reclassification of patients 
at risk of T2D. These findings are, however, not sufficient to bring these biomarkers 
into everyday clinical use. First, the findings should be extensively validated in other 
populations, preferably different from the ones studies in papers I-III. Second, the 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































to communicate, because they do not tell us whether the improvements translate into 
any significant clinical meaning. This especially concerns the lack of information on 
patients being reclassified away from the group(s) with intermediate risk, as can be 
obtained by the category-based NRI. Third, and perhaps most importantly,190 the 
current observational studies are insufficient to suggest that patients should be treated 
differently only on the basis of biomarker status alone. This is especially important 
among patients with established CHD, who presently receive generally similar 
treatment, at least in terms of medications and life-style advice. 
We used an NRI method based on logistic regression models in all three papers. 
For papers I and II we did also have information on the time to events, but had to 
(somewhat arbitrarily) use a cut-off of approximately three years of follow-up, because 
this was the approximate minimum follow-up for most patients. Therefore, patients 
who experienced an event after the cut-off period were actually classified as not 
experiencing an event, which, in addition to not taking into account the time-to-events 
per se, might have influenced the estimates. Notably, there has recently been launched 
a method for using Cox regression, instead of logistic regression, models when 
calculating the NRI, using the R package SurvIDINRI. However, this method also 
makes use of a selected cut-off in follow-up time, similar to our original approach, and 
consequently it did not alter the results to any particular extent when applied to the 
current data (data not shown). 
There has also recently been raised more profound criticism against the NRI. 
The NRI per se does not provide us of qualitative measures of the reclassification, i.e. 
whether unnecessary treatment (or testing) in some patients outweighs the incorrect 
reclassification of patients who later develop disease. This problem could be addressed 
by using analyses that take such weighting into account,191 which obviously 
necessitates the application of a category-based NRI. Moreover, the NRI may have 
several other limitations, as outlined by Leening et al,192 prompting carefulness when 
applying, reporting and interpreting results based on this methodology. 
Moreover, rather than being competitive, the C-statistic, the NRI, and the IDI 
seem to complement each other, and should therefore be reported together when 
assessing the incremental value of novel biomarkers in risk prediction models.157 We 
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did not calculate the IDI in paper I, but the IDI was reported in papers II and III. 
However, as advocated by others,192 paper I did report separate NRIs for events and 
non-events, which, due to space limitations, was not performed in paper II and III. 
5.2.9 BIOSAMPLE PROCESSING 
Routine laboratory measurements were performed on-site in both the WECAC and the 
NORVIT. We did not have detailed information on how these analyses were carried 
out, but it is not likely that established methods deviated considerably according to 
study sites, or introducing any serious bias according to the risk associations studied. 
Among SAP patients in the WECAC, study specific blood and urine samples 
were usually collected few days prior to or at the day of angiography, and immediately 
frozen. In the NORVIT, blood samples were collected on-site, and then shipped to the 
core laboratory at Bevital AS in Bergen before freezing. Thus, in the NORVIT, 
samples may have been exposed to room temperature for several days, which could 
have led to overestimating concentrations of plasma free choline, due to formation 
from PC at room temperature. Long-term storage at – 80 oC, however, most likely did 
not affect any of the choline metabolites.193 
In the NORVIT, we were able to adjust the DMG-mortality association for 
time-span from the index AMI until baseline biosampling, but contrary to the WECAC 
we did not have information on fasting status. However, it is likely that patients 
presenting with an acute AMI constitute of a mix of fasting and non-fasting patients at 
the time of biosampling, similar to the SAP patients in the WECAC, and this might be 
reflected by equal plasma DMG concentrations in both cohorts.  
5.2.10  STATISTICAL ANALYSES 
We have applied both traditional and more advanced statistical methods in the current 
thesis, and some have already been more thoroughly discussed in previous sections. 
Cox proportional and logistic regression modelling are robust and rely only on a 
few assumptions, in addition to having being the preferred statistical method in clinical 
endpoint studies for decades. However, it must be emphasized that relative risk 
estimates must be considered in light of absolute risk to more fully support their 
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clinical interpretability. In hindsight, this latter issue should perhaps have received 
more attention in all three papers. 
By using quantile (median) linear regression for baseline analyses, we obtained 
effect estimates that are easy to communicate with the readers, because we did not 
have to transform the variables. Non-parametric statistical tests tend to reduce the 
information conferred by the variables, since their distributions (hence also variances) 
are not accounted for when using parametric tests. The semiparametric quantile linear 
regression, on the other hand, not only provides us with a regression coefficient, but 
also allows us to examine the conditional distribution of a continuous variable 
according to all percentiles from 0-100. This makes it possible to explore potential 
differences across the distribution of the independent variable. We did, however, only 
focus on trend analyses according to the median (50-percentile) in the current work. 
Relationships in biological systems are seldom linear, which motivates the use 
of non-linear statistical approaches. We used GAM when exploring the associations 
between potential biomarkers and endpoint data, and presented the results as smoothed 
splines graphics. Whereas non-linear associations were not a major issue in paper I and 
II, several choline metabolites trended to deviate from linear relationships with 
incident T2D in paper III. This way of exploring and presenting data may provide 
more information in terms of potential underlying mechanisms, as well as avoiding the 
pitfall of concluding with no overall linear association in the case of a U-shaped 
relationship. We did not use non-linear models when assessing baseline or repeated 
measures data, which may pose limitations on their interpretability.  
5.3  ETHICAL CONSIDERATIONS 
5.3.1  LEGAL ASPECTS  
All patients included in the current thesis took part on a voluntary, non-commercial 
basis, and provided signed informed consent. The patient recruitment, diagnostic 
procedures, sample handling and import of endpoint data were performed according to 
the Declaration of Helsinki, approval from the Regional Medical Ethics Committee, 
and Norwegian law on health research.194 Moreover, all patients in the WECAC 
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underwent baseline angiography due to clinical indications, and not primarily for study 
purposes, thereby not exposing the patients to unnecessary hazard. 
5.3.2 FINANCIAL ISSUES 
The analyses of choline metabolites are presently not implemented in most routine 
laboratories. Therefore, the hypothetical implementation of choline metabolism 
biomarkers would likely add considerable cost if applied to large patient populations. 
Although such issues must be addressed in properly conducted cost-benefit-analyses, a 
potentially increment in expenditures is another ethical aspect to consider. 
5.4 DISCUSSION OF THE MAIN FINDINGS 
5.4.1  PUTTING THE FINDINGS INTO AN EPIDEMIOLOGICAL CONTEXT  
Papers I and II. The association between plasma DMG and an overall adverse CVD 
risk profile found in both papers I and II have not previously been reported. However, 
one study proposed an indirect relationship between plasma DMG and the extent of 
CAD at angiography according to the BHMT 742 G>A SNP,92 although a later meta-
analysis did not confirm any such relationship,195 thereby agreeing with our baseline 
findings in paper I.  
The prospective associations between DMG and adverse CVD prognosis are in 
line with results presented by Lever et al among approximately 500 New Zealand 
patients with a recent ACS.113 Although being secondary findings and not reaching 
statistical significance in models adjusted only for a limited number of potential 
confounders, the risk estimates in that study were similar to those reported by us in 
papers I and II. Our validation of the associations between plasma DMG and an 
adverse CVD prognosis in cohorts that were larger and had a more detailed baseline 
characterization and longer follow-up time, should be considered a strength. Further, 
by reporting the potential benefit of adding plasma DMG in risk prediction, and 
exploring temporal trends according to B-vitamin supplementation, the papers I and II 
extended current knowledge within the field. 
In secondary analyses, we also explored the relationships between other choline 
metabolites and risk of incident AMI in paper I. Plasma choline was weakly related to 
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the outcome, but was attenuated once DMG was introduced into the model, suggesting 
that DMG might have confounded previous reports on positive risk relationships 
between systemic choline concentrations and CVD events.111 We did not find any 
relationship between plasma betaine and incident AMI in paper I, nor was any such 
overall association evident among WENBIT patients with presumed SAP,196 thus 
opposing the findings by Lever et al;113 however differences in study outcomes may 
also relate to inequalities between the studied populations.   
Paper III. As stated above, previous studies suggested lower systemic betaine118-120 
and higher urine betaine57 among patients with established T2D as compared to their 
non-diabetic counterparts. Our prospective findings affirm these observations by also 
showing that low plasma betaine status, in addition to higher urine DMG and sarcosine 
predicted incident T2D. The trends were consistent in sensitivity analyses and when 
adjusting for traditional T2D risk factors, including age, BMI and HbA1c. These 
results indicate that alterations in choline- and one-carbon metabolism may be present 
before the onset of clinical disease, and might even predate features traditionally 
associated with increased T2D risk.  
A recent large Mendelian randomization study from Sweden found evidence of 
higher diabetes risk among patients with lower circulatory DMG concentrations as 
determined by polymorphisms in the gene coding for SDH.94 Although the association 
was weak, the authors concluded that DMG shortage might have a causal role in 
diabetes development, but did not report on the concomitant levels of other choline 
metabolites. Notably, the lack of systemic sarcosine data was actually highlighted as a 
limitation of the study.94 Indeed, if increased DMG catabolism was responsible for 
higher relative diabetes risk, one might suspect sarcosine levels to be positively 
associated with risk, as well. Also, increased downstream DMG metabolism should 
lead to a higher flux through the BHMT pathway, because of less product inhibition, 
hence possibly affecting betaine status. Our work reports on the concomitant risk 
relationships for all choline metabolites. We observed an overall null-effect between 
plasma DMG and TD2 risk in the multivariate model, and actually a trend towards a 
higher risk among those with particularly low serum sarcosine, thereby not 
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immediately supporting the conclusion made by the Swedish authors. It could be, 
however, that a favourable prognosis related to decreased DMG catabolism among 
subjects in the Swedish study rather reflected a betaine sparing effect; however a 
causal relationship between plasma betaine and diabetes was not supported in another 
Mendelian randomization investigating a specific BHMT polymorphism.197 Likewise, 
we did not find a significant difference in the incidence rate of T2D according to the 
BHMT 742 G>A in the WECAC (Table 6). We have not, however, assessed this 
relationship in more appropriate statistical models, nor have we investigated it in the 
NORVIT. 
The propensity to having high urine betaine excretion among patients with 
diabetes has been described in several smaller studies,57 and a recent report also 
showed that urine betaine and DMG was highly correlated among young healthy 
males,170 hence agreeing with our results in paper III.  
5.4.2 POSSIBLE MECHANISMS  
A general disclaimer. It must be emphasized that the present thesis primarily 
represents an epidemiological approach to the relationships between choline 
metabolism and non-communicable diseases. We have measured metabolites in body 
fluids, serving as proxies for very complex metabolic processes within subcellular 
compartments in various tissues. We are therefore not able to draw firm conclusions 
regarding mechanisms underlying metabolite status or risk relationships. However, 
previous, as well as the present studies, do suggest interesting, pathophysiological 
mechanisms in play. Also, these hypotheses may further serve as inspiration for new 
research projects, both within our own group, but hopefully also for others. 
Mitochondrial function, energy metabolism and lipid homeostasis. The transport 
of choline from the cytosol into the mitochondrion is assumed to be carrier-mediated, 
and the rate-limiting step in the conversion of choline into betaine.79 The inverse 
relationship between plasma choline and betaine with several CVD and T2D risk 
factors, as observed in our as well as in another112 study, could therefore relate to 
impaired choline transport across the mitochondrial membrane. Moreover, Chdh 
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knockout mice had accumulated choline and severely decreased mitochondrial betaine 
levels in certain tissues, which also exhibited disturbed mitochondrial function and 
morphology.198 Also, BADH is dependent on oxidized nicotinamide adenine 
dinucleotide (NAD+) as a cofactor,199 and preliminary studies from our group have 
shown that alterations in the downstream metabolism of tryptophan, essential in the 
production of NAD+, may relate to incident T2D. Taken together, this suggests that 
the choline-to-betaine conversion may be impaired among patients more susceptible to 
CVD and T2D. Plasma choline levels did not relate to prevalent or incident T2D in 
paper III; however any build-up of choline from decreased choline oxidation might be 
masked by increased use of choline for other purposes, including augmented hepatic 
lipid export when energy intake is high, as well as increased choline uptake by the 
kidneys.200 This issue could potentially be further explored by molecular tracer studies. 
In agreement with the epidemiological data, preclinical studies have also 
suggested inverse relationships between betaine levels and several indices of insulin 
sensitivity. For example, rat models of insulin resistance and T2D showed lower 
hepatic betaine levels, likely due to increased BHMT flux.201 This might also reflect 
the positive relationship between the HOMA2-IR and plasma DMG in paper II, 
although no such association was seen in other, and larger, populations.94 Moreover, 
betaine supplementation in insulin resistant rats improved insulin sensitivity in both 
the liver and in adipose tissue, possibly due to increased adipokine production and 
lowered endoplasmic reticulum stress.202  
Most data support an increased BHMT flux in obesity and insulin resistance; 
however whether this represents a compensatory mechanism, for example due to 
altered demands for methyl groups, or whether increased BHMT flux is detrimental, 
remains an open question. Nevertheless, it is interesting that no association between 
plasma DMG and T2D was observed in paper III, and that betaine status itself does not 
appear to be causally related to T2D risk, as discussed earlier. This might suggest that 
for betaine to excess favourable effects, there is a need of both sufficient betaine and 
an adequate BHMT function. On the other hand, BHMT knockout mice actually 
exhibited increased energy expenditure, reduced body fat and improved glucose 
metabolism and insulin sensitivity in adipose tissue,203 similar to choline deprived 
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mice, further complicating the interpretability in terms of BHMT flux. Professor 
Steven Zeisel addressed this discrepancy in a recent review.53 He proposed that 
different effects might arise from the influence by choline and betaine on PC 
composition, which again could affect insulin sensitivity via altered regulation of 
sterol regulatory element-binding protein 1.53 However, to make matters even more 
complex, high-dose betaine supplementation in healthy persons did not alter indices of 
the metabolic syndrome89 or resting energy consumption,204 although such therapy 
increased plasma betaine levels,89, 204 and thereby likely enhanced BHMT flux, as well. 
The link between BHMT and T2D may also relate to the association between 
statin therapy and increased risk of incident T2D.205 The BHMT function might 
actually be attenuated by statins, which were widely used in the WECAC population, 
because statin therapy has been related to higher plasma betaine in other,177 as well as 
in the WECAC cohort (data presented at the EuroPrevent Congress, Amsterdam, The 
Netherlands, 2014). Notably, simvastatin has been associated with impaired 
mitochondrial oxidative phosphorylation in skeletal muscle,206 thereby suggesting a 
potential relationship with deteriorations in the choline oxidation pathway.  
In line with our results, a metabolomics study among almost 900 young and 
healthy Italian men and women showed an inverse relationship between circulating 
DMG and LDL-cholesterol, total cholesterol, and triglycerides.207 We found 
particularly strong relationships between plasma DMG and CVD risk among those 
with low levels of (fasting) serum triglycerides and apoB 100. It is thus alluring to 
speculate whether the increased CVD risk for higher plasma DMG may be related to 
impaired downstream DMG catabolism. This could potentially decrease BHMT 
activity by product inhibition, and contribute to decreased VLDL output, as well as 
impaired oxidation of fatty acids.203 As treatment with folic acid likely attenuates 
BHMT flux, it is therefore interesting that we did observe a trend towards a stronger 
risk relationship between plasma DMG and incident AMI among those who received 
folic acid intervention in the WENBIT (Appendix 1; Supplemental Tables VI and 
VIII). A theory of BHMT inhibition is further supported by rat studies showing that 
peroxisome proliferation-activator alpha (PPARα) agonists, well-known for their 
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systemic triglyceride reducing abilities, likely impair DMG catabolism via down-
regulated expression of DDH and SDH.208  
The LDL hypothesis regarding ACVD holds firm ground, not least due to the 
recent results from the IMProved Reduction of Outcomes: Vytorin Efficacy 
International Trial (IMPROVE-IT)209 and results from clinical trials investigating 
treatment with proprotein convertase subtilisin/kexin type 9 antibodies.210, 211 
However, the provoking proposal of increased CVD risk by decreased hepatic VLDL 
cholesterol output212 lends support from the fact that non-alcoholic fatty liver disease 
(NAFLD) is indeed considered an independent CVD risk factor, and is also strongly 
related to T2D.213 In addition, studies in apoE knockout mice showed that betaine 
supplementation led to higher systemic levels of atherogenic lipids, but reduced body 
weight and atherosclerotic lesions,214 as well as relieving NAFLD. In line with these 
data, analyses in the WECAC show that glycine, the immediate sarcosine catabolite, is 
inversely related to incident AMI, and that the association is stronger when serum 
apoB levels are low.215 Notably, diminished GNMT flux has been shown to attenuate 
hepatic lipid export and induce hyperlipidemia,216 in addition to impairing reverse 
cholesterol transport and increasing atherosclerosis.217 Moreover, low systemic glycine 
levels have been related to higher risk of T2D.218 Glycine may be produced from other 
metabolic pathways than the SDH and GNMT reactions, as well;86 however our results 
may indirectly point to a high CVD and T2D risk when the lipid flux between the liver 
and peripheral tissues is reduced due to curtailed downstream choline oxidation. Hard 
clinical endpoint data to back up a theory of detrimental effects due to reduced hepatic 
VLDL export might be obtained from RCTs concerning treatment with mipomersen. 
This is an antisense oligonucleotide, which impairs hepatic VLDL efflux and lowers 
systemic LDL levels, but increases the risk of hepatic steatosis.219  
Further, it is interesting that choline- and one-carbon metabolism may also be 
related to apo A1 and HDL-cholesterol metabolism. Apo A1 is the major component 
of the HDL particle, low levels of which have been related to increased risk of both 
CHD and T2D, albeit Mendelian randomization studies have questioned causal 
relationships.220, 221 In line with previous epidemiological data,112 plasma betaine was 
negatively associated with both apoA1 and HDL-cholesterol in the WECAC. Also, 
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studies in mice have suggested that choline deficiency lowers systemic apo A1 
synthesis, probably due to reduced PPARα transcription,222 and that supplementation 
with betaine may improve apo A1 status.223 These effects could also indirectly relate to 
BHMT, since PPARα decreases flux through the CBS pathway.224  In addition, a 
betaine deficient state may lead to reduced BHMT flux and accumulating Hcy, the 
latter which may  lower apo A1 as well as HDL-cholesterol by several proposed 
mechanisms, as discussed by Obeid et al.225 
Ramifications to methyl metabolism, nucleotide production, cell turnover and 
epigenetic regulation. The interconversion of free folates between the mitochondrial 
and cytosolic compartments is limited, and one-carbon units therefore move from the 
mitochondrion to the cytosol mainly as glycine, serine or formate.79 Formate is used 
for purine synthesis, as it condenses with THF to form 10-formyl-THF.64 Furthermore, 
THF can be methylated by serine via the vitamin B6 dependent enzyme serine-
methyltransferase to generate 5, 10-methylene-THF, used for the production of 
thymidylate, and glycine.226 Consequently, altered metabolism down the choline 
oxidation pathway may influence the production of nucleotides necessary for DNA 
and RNA synthesis.227 In addition, reduced choline availability might affect genomic 
stability.227 These issues may have adverse effects on the cells’ regenerative and 
reparative abilities, and could be linked to cell apoptosis associated with vulnerable 
atherosclerotic plaques, 228 as well as apoptosis among cardiomyocytes being observed 
in CVD.229 The latter could, at least partly, be reflected by the strong positive 
relationship between plasma DMG and serum hs-cTnT among patients with suspected 
SAP (paper II), although adjusting for hs-cTnT did not alter the risk associations 
between DMG and mortality in the WECAC. The mechanisms involved in apoptosis 
are very complex; however, a propensity towards a catabolic state could potentially be 
relevant for other organs than the cardiovascular system, as well. Notably, patients 
with T2D are characterized by reduced mass of pancreatic beta cells, which may be 
ascribed to a mismatch in the dynamic process of cell replicating and apoptotic cell 
death.230  
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 Choline deficiency231 and impaired BHMT flux67, 232 are associated with lower 
hepatic SAM and increased SAH. The SAM/SAH ratio may reflect the methylation 
potential,233 and although partially compensated for by up-regulation of 
methyltransferases,64 a lower methylation potential due to impairments along the 
choline oxidation pathway could influence epigenetic regulation in terms of reduced 
methylation of cytosine-guanine repeat (CpG) islands in the DNA.234 However, the 
extreme complexity of interactions between genes makes it difficult to predict how an 
overall reduction in methylation capacity may influence phenotype or prognosis. 
Reflecting this complexity, DNA hypo- and hypermethylation may coexist at specific 
regions within the genome, yet several studies have associated global DNA 
hypomethylation with atherosclerosis.235, 236 Moreover, DNA methylation is inversely 
associated with age,237 the latter being far the most important predictor of adverse 
CVD prognosis in both the WECAC and the NORVIT cohorts (data not shown).  
Epigenetic regulation is also important in glucose and energy metabolism,235 as 
well as in T2D. The role of methylation was further highlighted in a study among 
nicotinamide N-methyltransferase knocked-out mice, which had a propensity to 
leanness because of increased energy expenditure. This was explained by increased 
SAM available for methylation reactions including polyamine synthesis in peripheral 
adipose tissue, as well as higher flux of oxidized nicotinamide adenine dinucleotide 
(NAD+).238 Betaine supplementation was also associated with increased hepatic SAM 
levels in fat-fed, insulin resistant mice,239 and a recent study indicated that improved 
methylation status from betaine might favorably influence several enzymes involved in 
lipogenesis and fatty acid synthesis, including the fat mass and obesity-associated 
(FTO) gene.240   
Choline metabolites in the urine. It is plausible that systemic choline metabolite 
status primarily reflects altered metabolism in the liver, whereas urinary 
concentrations of choline metabolites mirror their handling and/or metabolism in the 
kidney. This is supported by the relative modest correlations between systemic and 
urinary levels of choline metabolites in the WECAC (paper III), and the low 
correlation reported between plasma and urinary betaine in previous studies.57 
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However, we observed a negative correlation between baseline plasma and urine 
betaine among patients with established T2D (paper III), indicating that patients with 
overt disease actually may have urinary betaine loss contributing to low systemic 
betaine levels. This agrees with the findings by Lever et al, who reported that some 
patients with T2D might actively excrete betaine from the kidneys, thereby exceeding 
100% fractional clearance for betaine.241  
Urine betaine excretion has been positively associated with parameters of 
impaired glucose control in patients with diabetes;125, 241, 242 however the increase may 
not be dependent on high systemic glucose levels per se,243 but a link to 
hyperosmolarity has been suggested.57  Proximal tubular dysfunction has been 
proposed as a likely contributor to increased urinary betaine excretion among patients 
with diabetes, because betaine is freely filtered in the glomeruli and urine betaine is 
correlated with urinary concentrations of retinol binding protein, a marker of tubular 
dysfunction.242 This corresponds to our findings in paper III, since the predictive 
ability of urine betaine, as well as DMG and sarcosine, was independent of 
microalbuminuria which primarily reflects glomerular leakage.244 Our findings extend 
previous data, as we also observed that patients who later developed T2D had a 18% 
and 23% increase in baseline urine betaine and sarcosine concentrations, respectively, 
as compared to those who did not develop T2D (Article III). A 9.9% increase in urine 
DMG was also observed; however this difference was not statistically significant. 
These differences did not seem to be explained by reverse causation due to 
misclassification of T2D at baseline, as urine choline metabolites levels were similar 
among patients with possible and patients without T2D. This suggests that altered 
renal handling and/or metabolism of choline metabolites is present before the onset of 
overt T2D.  
As compared to betaine, relatively little attention has previously been paid to 
urinary DMG and sarcosine excretion. Betaine ingestion is associated with a transient 
increase in urine DMG concentration, and a slightly higher fractional excretion has 
been reported for DMG than for betaine in pigs.57 Treatment with fibrates, which are 
PPARα agonists, has also been related to a massive increase in both urine betaine and 
DMG, and especially so among patients with T2D.241, 245 Moreover, urine betaine and 
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DMG correlated strongly with urine choline in another study, which also reported that 
fenofibrate led to larger increments in urine betaine, than DMG and choline.245 In 
paper III, urine choline was not associated with incident T2D; however it is plausible 
that betaine and DMG, and perhaps also other choline metabolites, may have some 
common renal handling, also in terms of active excretion from renal epithelial cells.241, 
245
Almost no sarcosine is excreted in the urine among normal subjects.246 Higher 
urinary sarcosine levels have been observed among patients with impaired SDH,247 
probably reflecting the role of sarcosine in scavenging excess methyl.85 Most sarcosine 
filtered in the glomeruli is assumed to be absorbed in the tubular system, and sarcosine 
may compete with glycine for reuptake in tubuli.247 One might therefore speculate 
whether increased sarcosine excretion partly results from enhanced renal glycine 
uptake in a glycine deficient state being associated with T2D. Our data does not 
support this, however, as urine glycine concentrations did not relate to T2D in the 
WECAC (data not shown). 
Both GNMT248 and BHMT48 are abundant in the kidneys, and increased flux 
over these enzymes, at least locally, could perhaps lead to a spill-over of products from 
renal cells and into the tubulus system. On the other hand, insulin resistance and T2D 
may affect GNMT differently in the kidney as compared to the liver. For example, 
renal GNMT flux might not be up-regulated in prediabetic state, as is the case in the 
diabetic state. This somewhat contrasts hepatic GNMT flux, which is most likely up-
regulated in both conditions.249 We also observed that treating the patients with B-
vitamins altered systemic choline metabolites during follow-up, most probably related 
to reduced BHMT flux; however less consistent findings were made in the urine. 
Potential tissue specific alterations in BHMT and GNMT flux brought about by insulin 
resistance and T2D therefore makes it problematic to draw firm conclusions when only 
metabolite concentrations in the blood and urine are measured.  
Can dietary factors explain our findings? In paper III, we also had data available on 
estimated daily intake of both choline and betaine in a subpopulation of the WECAC 
participants, suggesting the daily intake of choline to be far below that recommended 
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by USDA.52 We did not, however, find any differences in these measures according to 
T2D, although plasma TMAO, a proposed marker of choline intake,102 was about two-
fold among those with existing T2D at baseline, the latter agreeing with previous 
observations.120, 123, 250 Moreover, recent studies actually found lower plasma TMAO 
and betaine levels to predict gestational diabetes in women,251, 252 thereby complicating 
the relationship between TMAO and diabetes risk further. Higher intakes of PC were 
recently related to increased T2D risk;122  however, we did not explore dietary 
determinants of choline metabolites, nor did we assess the relationships between total 
choline and betaine intake with the risk of new-onset T2D per se. Nevertheless, 
including data on choline and betaine intake in the multivariate models in paper III did 
not affect the risk estimates, nor was plasma TMAO predictive of incident T2D in 
general.  
A recent study actually questioned the alleged causal association between 
plasma TMAO and ACVD, redirecting the focus to hepatic FMO3 instead.253 
Accordingly, preliminary results from the WECAC also challenge the relationship 
between plasma TMAO and CVD risk. This agrees with previous epidemiological data 
reporting no statistically significant associations between intakes of choline and 
betaine with incident CVD116, 117, 254  
Relatively weak associations between dietary factors and plasma choline and 
betaine levels have previously been reported.55 Although we did not estimate 
methionine intake, it therefore seems reasonable to conclude that dietary intake of 




The aims of our patient population studies were to investigate prospective risk 
relationships between plasma DMG with incident AMI and mortality, as well as 
systemic and urinary choline metabolites in relation to incident T2D. Additionally, we 
explored temporal changes in systemic and urinary choline metabolites, also according 
to treatment with B-vitamins crucial for enzymes in the choline oxidation pathway. In 
conclusion, the current thesis answered the study aims as follows: 
6.1  STUDY I  
Plasma DMG was positively associated with the risk of incident AMI during about 
four and a half years of follow-up. The risk associations were independent of 
traditional CHD risk factors and remained also when adjusting for potential 
confounders. Adding plasma DMG to a model of traditional CHD risk factors 
improved model discrimination and suggested enhanced classification of patients at 
risk. Treatment with folic acid and vitamin B12 lowered plasma DMG levels during 
repeated measures. Among patients allocated to placebo treatment, plasma DMG 
showed excellent test-retest reliability. 
6.2  STUDY I I 
Plasma DMG was positively related to long-term risk of all-cause and CVD mortality 
in two independent cohorts of patients with suspected SAP and AMI, respectively. The 
risk associations did not seem to be explained by traditional CVD risk factors, nor by 
potential confounders, and there were indications of improved risk prediction for 
plasma DMG beyond traditional CVD risk factors. The attenuation of temporal plasma 
DMG increments by combined folic acid and B12 treatment was consistent in both 
cohorts, as was the within-person reproducibility of plasma DMG. 
6.3  STUDY III  
Low plasma betaine and high urine betaine, DMG and sarcosine were related to 
increased risk of incident T2D throughout 7 years of follow-up. The risk relationships 
were not dependent on several T2D risk factors or potential confounders, and adding 
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either plasma betaine or urine sarcosine suggested improved model discrimination and 
reclassification of patients at risk. Both metabolites also showed good within-person 
reproducibility. As compared to placebo, treatment with folic acid with or without 
vitamin B6 led to relative increases in plasma choline and betaine, but decreases in 
plasma DMG and serum sarcosine. Similar, although less pronounced alterations were 
seen for urine choline metabolites. 
Our results partly provide important validation on previous results in smaller 
epidemiological studies, but also add new knowledge into the field of choline 
metabolism. As described above, the present thesis therefore generates several novel 
hypotheses relating to diseases like CVD and diabetes, which determinate morbidity 
and mortality worldwide, thereby warranting further studies within this research field. 
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7 FUTURE PERSPECTIVES
Our research group will continue to explore the choline oxidation pathway in relation 
to CVD and T2D, with a particular focus on lipid and energy homeostasis.  
We are currently in the process of linking both the WECAC and the NORVIT 
cohorts (collectively named the Norwegian Study on Coronary Heart Disease; 
NORCAD) with data from extended follow-up on incident CVD events and mortality 
throughout 2009, thereby providing us with even more reliable risk estimates; however 
we must also keep in mind that any potential effect modification by WENBIT and 
NORVIT intervention might be diluted when analyzing these extended follow-up data. 
Moreover, the research group is also applying for linkage between the NORCAD and 
the Norwegian prescription database, which will hopefully allow for more accurate 
identification of incident cases of diabetes, as well as the ability for exploring risk 
associations according to pharmacological treatment and patients’ metabolic profiles. 
In the dawn of the “big data” era it seems imperative that researchers across 
groups and borders take advantage of each other’s data material, in order to optimize 
publicly funded projects. We therefore also seek to extend our collaboration with other 
research environments, not least to validate epidemiological findings, but also because 
experimental research among both animals and humans will provide valuable 
information on novel pathophysiological pathways. For example, a human dietary 
intervention trial is about to be launched in our department, partly based upon findings 
from studies of choline- and one-carbon metabolites in relation to dietary intake 
patterns in the WENBIT, as well as experiments on mice carried out by the 
collaborating Lipid Research Group at the University of Bergen.  
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Supplementary table 2. Choline metabolites at baseline and after 1 




placebo (ref) 9.0 (8.3, 9.7) 8.5 (7.7, 9.3)
FA+B12+B6 8.2 (7.5, 8.9) 7.6 (6.9, 8.4)
FA+B12 8.6 (7.9, 9.3) 7.9 (7.1, 8.6)
B6 7.7 (6.9, 8.4) 7.6 (6.9, 8.4)
choline
placebo (ref) 9.8 (9.6, 10.0) 10.4 (10.2, 10.7)b
FA+B12+B6 9.7 (9.5, 9.9) 11.0 (10.7, 11.2)c
FA+B12 9.7 (9.5, 9.9) 11.0 (10.7, 11.2)c
B6 9.9 (9.7, 10.2) 10.5 (10.2, 10.7)
betaine
placebo (ref) 40.7 (39.6, 41.8) 43.1 (42.0, 44.4)b
FA+B12+B6 40.7 (39.6, 41.8) 49.6 (48.4, 50.8)d
FA+B12 41.0 (39.9, 42.1) 48.1 (47.0, 49.3)d
B6 42.0 (40.8, 43.1) 45.1 (44.0, 46.3)
dimethylglycine
placebo 4.4 (4.3, 4.6) 4.6 (4.4, 4.7)a
FA+B12+B6 4.2 (4.1, 4.4) 4.1 (4.0, 4.3)c
FA+B12 4.4 (4.2-4.5) 4.3 (4.2-4.5)c
B6 4.2 (4.0-4.3) 4.5 (4.3-4.6)c
sarcosine
placebo 1.63 (1.57-1.68) 1.89 (1.76-2.03)b
FA+B12+B6 1.61 (1.56-1.66) 1.55 (1.43-1.68)d
FA+B12 1.58 (1.53-1.63) 1.55 (1.41-1.69)c
B6 1.59 (1.54-1.64) 1.66 (1.52-1.80)c
Urine, mmol/mol creatinine
choline
placebo 1.98 (1.87-2.10) 2.20 (1.09-2.32)b
FA+B12+B6 2.13 (2.02-2.24) 2.35 (2.24-2.47)
FA+B12 2.12 (2.01-2.23) 2.29 (2.17-2.40)
B6 2.13 (2.02-2.24) 2.14 (2.03-2.26)c
betaine
placebo 10.0 (9.0-10.9) 10.5 (9.6-11.5)
FA+B12+B6 9.3 (8.4-10.2) 11.0 (10.0-11.9)
FA+B12 9.3 (8.4-10.3) 10.0 (9.1-11.0)
B6 9.5 (8.6-10.4) 9.8 (8.9-10.8)
placebo 4.1 (3.7-4.4) 4.5 (4.1-4.9)b
FA+B12+B6 3.8 (3.4-4.1) 3.6 (3.2-3.9)d
FA+B12 3.7 (3.4-4.1) 3.6 (3.2-3.9)d
B6 3.6 (3.3-4.0) 3.8 (3.5-4.2)
sarcosine
placebo 0.18 (0.16-0.19) 0.19 (0.18-0.20)a
FA+B12+B6 0.16 (0.15, 0.17) 0.13 (0.12, 0.14)d
FA+B12 0.17 (0.16, 0.18) 0.13 (0.11, 0.14)d
B6 0.16 (0.15, 0.17) 0.18 (0.16, 0.19)
Values are given as mean (95% confidence interval).
B6, vitamin B6; B12, vitamin B12; FA, folic acid; TMAO, 
trimethylamine N-oxide; WENBIT, Western Norway B-Vitamin
Intervention Trial.
aP<0.05 for difference from baseline; bP<0.001 for difference from









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary table 5. The intraclass correlation coefficients for plasma betaine and urine 
sarcosine over 1 year
ICC (95% CI)
Placebo FA + B12 + B6 FA + B12 B6
Plasma betaine 0.62 (0.56, 0.66) 0.43 (0.36, 0.50) 0.44 (0.37, 0.51) 0.65 (0.60, 0.70)
Urine sarcosine 0.69 (0.64, 0.74) 0.49 (0.41, 0.56) 0.37 (0.28, 0.46) 0.73 (0.68, 0.77)
B6, vitamin B6; B12, vitamin B12; CI, confidence interval; FA, folic acid; ICC, intraclass correlation 
coefficient.
